Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a communitybased cohort in Fukushima, Japan

AUTHORS:

Naotoshi Nakamura^{1,†}, Yurie Kobashi^{2,3,†}, Kwang Su Kim^{1,4,5,†}, Yuta Tani⁶, Yuzo Shimazu², Tianchen Zhao², Yoshitaka Nishikawa³, Fumiya Omata³, Moe Kawashima², Makoto Yoshida⁶, Toshiki Abe², Yoshika Saito⁶, Yuki Senoo⁶, Saori Nonaka², Morihito Takita², Chika Yamamoto², Takeshi Kawamura^{7,8}, Akira Sugiyama⁷, Aya Nakayama⁷, Yudai Kaneko^{8,9}, Hyeongki Park¹, Yong Dam Jeong^{1,5}, Daiki Tatematsu¹, Marwa Akao¹, Yoshitaka Sato¹⁰, Shoya Iwanami¹, Yasuhisa Fujita¹, Masatoshi Wakui¹¹, Kazuyuki Aihara¹², Tatsuhiko Kodama⁸, Kenji Shibuya^{13,14}, Shingo Iwami^{1,15,16,17,18,19,‡,*} and Masaharu Tsubokura^{2,3,6,20,‡,*}

AFFILIATIONS:

¹interdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan. ²Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan. ³Department of General Internal Medicine, Hirata Central Hospital, Fukushima, Japan. ⁴Department of Science System Simulation, Pukyong National University, Busan, South Korea. ⁵Department of Mathematics, Pusan National University, Busan, South Korea. ⁶Medical Governance Research Institute, Tokyo, Japan. ⁷Proteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo, Japan. ⁸Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. ⁹Medical & Biological Laboratories Co., Ltd, Tokyo, Japan. ¹⁰Department of Virology, Nagoya University Graduate School of Medicine, Nagoya, Japan. ¹¹Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan. ¹²International Research Center for Neurointelligence, The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Tokyo, Japan. ¹³Soma Medical Center of vaccination for COVID-19, Fukushima, Japan.¹⁴Tokyo Foundation for Policy Research, Tokyo, Japan. ¹⁵Institute of Mathematics for Industry, Kyushu University, Fukuoka, Japan. ¹⁶Institute NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan. ¹⁷Interdisciplinary Theoretical and Mathematical Sciences Program (iTHEMS), RIKEN, Saitama, Japan. ¹⁸NEXT-Ganken Program, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan. ¹⁹Science Groove Inc., Fukuoka, Japan. ²⁰Minamisoma Municipal General Hospital, Fukushima, Japan.

†,‡ These authors contributed equally to this study.

*To whom correspondence may be addressed.

Email: <u>iwami.iblab@bio.nagoya-u.ac.jp</u> (S.I.) and <u>tsubo-m@fmu.ac.jp</u> (M.T.).

1 Abstract

2 Recent studies have provided insights into the effect of vaccine boosters on recall immunity. Given the limited global supply of COVID-19 vaccines, identifying vulnerable 3 4 populations with lower sustained vaccine-elicited antibody titers is important for targeting 5 individuals for booster vaccinations. Here we investigated longitudinal data in a cohort of 2,526 people in Fukushima, Japan, from April 2021 to December 2021. Antibody titers following two 6 7 doses of a COVID-19 vaccine were repeatedly monitored and information on lifestyle habits, 8 comorbidities, adverse reactions, and medication use was collected. Using mathematical 9 modeling and machine learning, we stratified the time-course patterns of antibody titers and 10 identified vulnerable populations with low sustained antibody titers. Moreover, we showed that 11 only 5.7% of the participants in our cohort were part of the "durable" population with high sustained 12 antibody titers, which suggests that this durable population might be overlooked in small cohorts. We also found large variation in antibody waning within our cohort. There is a potential usefulness 13 14 of our approach for identifying the neglected vulnerable population.

15 Main Text

16 Primary two-dose coronavirus disease 2019 (COVID-19) vaccination leads to rapid immunity, providing protection against severe acute respiratory syndrome coronavirus 2 (SARS-17 18 CoV-2) infection¹. Although COVID-19 vaccines still offer good protection against severe disease and death for months after the second dose owing to the durability of immunity²⁻⁴, the waning of 19 vaccine efficacy has become a major concern in the era of "living with COVID-19"⁵⁻⁹. The rapid 20 21 decline in vaccine-elicited antibodies results in breakthrough infections and adverse health 22 outcomes caused by emerging variants of concern (VOCs), including the Beta, Delta, and Omicron variants¹⁰⁻¹³. Additional third and fourth doses of vaccine induce a high-level antibody 23 response against VOCs¹³⁻¹⁷, implying a need for additional booster vaccinations as a future 24 pandemic exit strategy¹⁸⁻²⁰. Few studies, however, have quantitatively stratified and assessed the 25 26 variation in waning of antibody titers at both the population and individual level in a communitybased large cohort. 27

28 At the population level, it is well known that the older a person is, the faster their protection 29 weakens after the second vaccination^{7,8}, and that people with underlying medical conditions tend to induce an insufficient antibody response^{8,21}. These populations are generally the highest 30 31 priority group for booster vaccinations. There is, however, large variation in the vaccine-elicited antibody response at the individual level, even within the same age group^{6-8,15,21,22}. Assessing the 32 factors that affect such variations will shed further light on our understanding of waning of 33 34 protection and identify potentially vulnerable populations that may be a priority for booster 35 vaccination^{8,21}. In the long-run, personalized vaccination will be required, because continuous 36 vaccinations after the third dose to the whole population may be neither sustainable nor feasible 37 globally. One approach to assess variation within the same group of people is the stratified analysis of time-dependent vaccine-elicited antibody dynamics. 38

Although the mean time-dependent vaccine efficacy for symptomatic and severe SARS CoV-2 infections has been assessed through cross-sectional and longitudinal studies at the

41 population level^{2,3}, many relevant aspects of the individual-level time course of antibody dynamics 42 and the variations in individual-level dynamics are not well understood. In this study, we collected 43 longitudinal datasets on individual antibody responses, together with personal information including lifestyle habits, comorbidities, adverse reactions, and medication use, from more than 44 45 2,526 individuals of a community-based cohort in Fukushima, Japan. Taking advantage of this 46 unique cohort and using mathematical modeling and machine-learning approaches, we stratified 47 the elicited immune response after two doses of a COVID-19 vaccine by reconstructing individual antibody dynamics. Furthermore, we explored the factors associated with the durability of vaccine 48 49 response. Our aim was to understand individual-level variation in vaccine-elicited immune 50 responses at the time of booster vaccinations and to inform long-term COVID-19 vaccination 51 strategies.

52 **Results**

53 **The Fukushima vaccination cohort**

54 This study was conducted from April 2021 to December 2021 in Fukushima, Japan. Our vaccination cohort consisted of participants from a primarily rural area where COVID-19 55 prevalence was relatively low: Soma City, Minami Soma City, and Hirata village (Fig 1A). The 56 57 participants included health care workers, frontline workers, administrative officers, general residents, and residents of long-term care facilities. In total, 2,526 participants who had been 58 vaccinated with the Pfizer BNT162b2 or Moderna mRNA-1273 vaccine were recruited, and 2,159 59 60 participants were included in the final data analysis, respectively (see **Fig 1B** and **Methods** in details). The age and sex distributions of the participants are shown in **Fig 1C**, and the sample 61 62 characteristics and information on adverse vaccine events stratified by age are provided in 63 **Extended Data Table 1.** A portion of this cohort was described previously for the time period 64 extending to 6 months after the first dose of mRNA vaccine^{23,24}.

65 Here we investigated antibody titers in the Fukushima cohort in individuals sampled longitudinally (serum was collected at 2 or 3 different timepoints) for around 4 to 9 months after 66 the second primary dose of mRNA vaccine (see Fig 1DE for details). Notably, the number of 67 SARS-CoV-2 infections in this rural area was extremely low (Fig 1E), so that we could minimize 68 69 the influence of breakthrough natural infections. The Fukushima cohort, which is large enough 70 and with a long study period (Fig 1F), is an ideal longitudinal cohort for quantifying and stratifying vaccine-elicited antibody dynamics (Supplementary Note 1 and Supplementary Table 1). In 71 72 particular, compared with the largest cohort of more than 3,900 participants from Israel,⁶ the 73 Fukushima cohort is community-based, includes non-health workers, has very few dropouts 74 among more than 2,000 identical individuals who were consecutively sampled (only 3.3%), includes all necessary information for all participants, and includes measures of several 75 76 modalities of antibody titers including neutralizing activity (Supplementary Table 2).

We performed chemiluminescent immunoassay (CLIA) to measure antibody titers as a measure of humoral immune status after the first COVID-19 vaccination (i.e., a total of 5195

79 IgG(S), 5195 neutralization activity, and 4969 IgG(N) assays were performed) (Methods). Fig 1G shows the overall profile of IgG(S) and neutralization activity in this study. We investigated 80 81 longitudinal data for IgG(S) in the same individuals because IgG(S) covers a wider range of antibody responses and is more sensitive than neutralization activity. In fact, these two 82 83 measurements are highly correlated with each other (correlation coefficient of 0.93) (Extended 84 **Data Fig 1AB**), and previous studies showed that neutralizing antibody and IgG(S) titers correlate 85 with vaccine-mediated protection, even against VOCs (i.e., vaccine efficacy)¹⁻³. This is because vaccines containing the original Wuhan virus spike protein induce variant-reactive memory B cells 86 targeting multiple different VOCs, including the Omicron variant¹⁵. 87



88 Figure 1 | Characteristics of the Fukushima vaccination cohort: (A) Locations of Soma city, 89 Minami Soma city, and Hirata village in Fukushima prefecture are described. (B) Flowchart of the 90 vaccination cohort along with the number of participants, testing, and inclusion criteria for our analysis are described. (C) Age and sex distributions in the cohort are shown. (D) Timeline of 91 92 sample collection for each cohort participant (N=2,526 participants, 5195 total samples) is described. The timings of blood samplings are indicated in black circles. Shaded areas indicate 93 94 early (<89 days), middle (90-179 days), and late (>180 days) time periods after the first 95 vaccination. Dates for the second vaccination are shown as the distributions in the bottom panel. (E) Vaccination and blood sampling periods in the cohort along with the number of COVID-19 96 cases (i.e., cases) in Soma city, Minami Soma city, and Hirata village^{48,49} are shown. (F) 97 98 Distribution of the study periods and the number of participants (i.e., cohort size) of previously 99 reported cohorts extracted by literature review (Supplementary Note 1) are plotted along with 100 the Fukushima vaccination cohort (the red mark). The closed and open marks correspond to cohorts with and without questionnaire data. The origin of coordinates corresponds to the median 101 of the period and number of the cohorts, and the whiskers indicate corresponding standard 102 derivations. (G) Longitudinal IgG(S) and neutralizing activity measured by CLIA are separately 103 plotted by time after the first vaccination and age. 104

105 Stratification of vaccine-elicited time-course antibody dynamics

106 We developed a mathematical model describing the vaccine-elicited antibody dynamics to evaluate the impact of primary two-dose COVID-19 vaccination on rapid immunity at the 107 individual level and reconstructed the best-fit antibody titer curves of 2,407 participants in the 108 109 Fukushima cohort (details are provided in the **Methods**). We then performed an unsupervised 110 clustering analysis using a random forest dissimilarity to stratify the time-course patterns of antibody dynamics into six groups (i.e., G1 to G6) (details in Supplementary Note 2). Fig 2A 111 represents a two-dimensional Uniform Manifold Approximation and Projection (UMAP) 112 113 embedding of these six groups, which clearly shows that G5 and G6 are separated from the other groups. Using a different color for each group, we also plotted the reconstructed individual 114 antibody dynamics after 25 days after the first vaccination as shown in Fig 2B (see also Extended 115 **Data Fig 2D**). The projected time course of each group showed that sustained antibody titers 116 remained high among individuals in G1 (i.e., the "rich" responder group), whereas those in G5 117 and G6 were low (i.e., "poor" responders) (Fig 2C). We classified G1 as a "durable" population 118 and G5/G6 as a "vulnerable" population in our analysis. In contrast, individuals in G2, G3, and G4 119 120 showed intermediate dynamics. Note that most individuals in the Fukushima cohort had no history 121 of natural infection (i.e., only 1.07%).

Next, we investigated the age dependency of the 6 groups (**Fig 2D**): G1/G2, G3/G4, and G5/G6 consisted mainly of people aged 0 to 39 years (young), 40 to 64 years (middle age) and 65 to 100 years (old), respectively. Most individuals were stratified into G3 or G2, the representative population of the Fukushima cohort (**Fig 2E**). Although the age distributions of G1/G2 and G3/G4 were similar, individuals in G2 and G4 showed a relatively rapid decay in antibody response after the second dose compared with those in G1 and G3, respectively (**Extended Data Fig 2D**).

The longitudinal IgG(S) and neutralizing activity measured by CLIA are separately plotted into three different periods (i.e., 0-89, 90-179, \geq 180 days) by taking into account the stratified groups in **Fig 2F**. Both IgG(S) and neutralizing activity decreased as age increased and time

passed. More precise predictions (i.e., at a specific date at an individual level rather than during
 a specific period at a population level) were made possible with our reconstructed individual-level
 antibody dynamics (**Fig 2G**).

To further evaluate the vaccine-elicited immunity, we calculated the fraction of individuals 135 with antibody titers of IgG(S) below set thresholds (i.e., 10 and 200 arbitrary unit/mL [AU/mL]) 136 (Fig 2H). As reported in the study by Nakano et al.²⁵, 10 AU/mL is a clear threshold for 137 unvaccinated individuals, meaning that individuals showing titers less than this threshold have no 138 vaccine efficacy at all. In contrast, so far, there are no clear thresholds for quantifying vaccine 139 efficacy, as intensively discussed in Cromer et al.² and Khoury et al.³. Here we used the value of 140 200 AU/mL as an indicator for the efficacy threshold, because more than 80% of vaccinated 141 142 persons maintained their antibody titers above 200 AU/mL during the early period (i.e., for at most 3 months after the first vaccination) regardless of group in our cohort (see the top-left panel in Fig 143 **2F**). Our simulations showed that most of the durable population (i.e., G1) maintained their 144 vaccine efficacy for at least 8 months, and furthermore, around 13% of them still did not show a 145 146 loss of vaccine efficacy for 1 year after the first vaccination (Fig 2H). On the other hand, the vulnerable populations (i.e., G5/G6) showed a low induction of antibody titers after the second 147 dose and rapid decay in efficacy; approximately 50% of them had very low antibody titers after 1 148 149 year, which were comparable to those in unvaccinated persons. Individuals in G4 showed a high initial induction of antibody titers after the second dose but a rapid decay; approximately 95% of 150 151 them showed a loss of vaccine efficacy after 1 year.

For our sensitivity analysis, we used the threshold of 80 AU/mL, which corresponds to "strong positive" as defined in the Mount Sinai Health System²⁶ and obtained the same conclusions (e.g., **Supplementary Fig 1A** for 80 AU/mL).

155



Figure 2 | Stratification of vaccine-elicited antibody response: (A) UMAP of stratified antibody 156 responses to mRNA vaccination based on the extracted features from the reconstructed 157 158 individual-level antibody dynamics are shown. Data points represent individual participants and are colored according to group (i.e., G1 to G6). (B) The reconstructed individual antibody 159 dynamics after 25 days after the first vaccination in each group are shown. (C) The time-course 160 patterns highlighted by Partial Least-Squares Discriminant Analysis (PLS-DA), which 161 discriminates each group from the others, are shown. The individual dynamics after 25 days after 162 the first vaccination were projected onto the direction of the first latent variable. The horizontal 163 164 dashed lines at 200 and 10 AU/mL correspond to the thresholds of "vaccine efficacy" and unvaccinated persons, respectively. The vertical dotted lines represent 180 and 240 days after 165 the first vaccination. (D) Age distribution in each group along with its fraction (%) and the number 166 of individuals (n) is shown. (E) Group distribution by age (i.e., 0-39, 40-64, 65-100) is plotted in 167 pie charts. (F) Measured IgG(S) and neutralizing activity in each group are plotted in the early, 168 middle, and late period. (G) Simulated IgG(S) titers from reconstructed individual-level antibody 169 170 dynamics at 60, 180, and 240 days after the first vaccinations are plotted. (H) Fraction of 171 individuals with antibody titers <10, 10-200, and 200 < AU/mL in each group at 180, 240, and 365 172 days are plotted as black, white, and group color, respectively, in pie charts. All correlations were calculated as Pearson correlation coefficients. 173

174 Characterizing vulnerable and durable populations

Multiple factors, including underlying medical conditions, drug history, and immune competency, may contribute to the stratification of the study population. For example, there was substantial variation in sustained immunity within the same age group (e.g., age distributions in both the durable and vulnerable populations were wide), and about 7% of the vulnerable population in G5/G6 were young individuals (0-39 years of age) (**Fig 2E**).

To further characterize each stratified group, we trained a random forest classifier to 180 predict the group from the sample characteristics of 2159 individuals in the Fukushima cohort 181 182 (see Extended Data Table 1), and obtained ROC-AUCs of 64.4%, 69.3%, and 70.9% for predicting G1 (the durable population), G2, and G1/G2, respectively (Fig 3A). Analysis of the 183 feature importance suggested that adverse reactions (e.g., headache and joint pain) were 184 significant predictors common to both G1 and G2 (Fig 3C). On the other hand, we achieved ROC-185 AUCs of 78.0%, 75.1%, and 80.8% for predicting G5, G6, and G5/G6 (the vulnerable populations), 186 respectively (Fig 3B). Various factors including age, the interval between the two doses, 187 188 comorbidities, and medication use were listed as the significant predictors of G5 and/or G6 (Fig **3D**). This finding was consistent with the results of our literature review (see **Supplementary** 189 **Table 3**). We were not able to achieve a high ROC-AUC for predicting G3 and G4, the groups 190 into which the majority of our cohort participants fell (see Extended Data Fig 3A and Discussion). 191 Furthermore, when the classifier for G5/G6 was trained after the population was stratified 192 193 according to age (i.e., 0-39 [young], 40-64 [middle age], and 65-100 [old]), the ROC-AUCs were 194 69.3%, 68.7%, and 70.1%, respectively (see **Extended Data Fig 3B**). Our analysis of the feature importance suggested that medication use (e.g., anti-cancer agents, steroids, 195 and 196 immunosuppressants) was a significant predictor for young people, whereas alcohol consumption and smoking played an additional role for middle-aged persons (Fig 3E). The detailed inter-197 relationship of the various features described in Fig 3F and Extended Data Fig 3C are explained 198 199 in Supplementary Note 3.



Figure 3 | Characterization of vulnerable and durable populations: (A) and (B) show the ROC 200 curves of random forest classifiers trained on predicting either G1 (durable population); G2 or 201 G1/G2; and G5, G6, or G5/G6 (vulnerable population), respectively. The corresponding AUC 202 value of each ROC curve is calculated on the top of each panel. (C) and (D) show the most 203 predictive features (feature importance) of G1, G2, and G1/G2 and G5, G6, and G5/G6 as Chord 204 205 diagrams, respectively. Each feature is represented by a fragment on the outer part of the circular 206 layout. The size of the arc from a group to a feature is proportional to its importance as measured by mean decrease in accuracy. Features with p < 0.05 are displayed. (E) The most predictive 207 features of G5/G6 in young, middle-aged, and old populations are calculated and shown as a 208 Chord diagram. Features with p < 0.05 are displayed. (F) Principal component analysis of 209 210 various features is shown. The colored ellipses represent 90% data ellipses drawn for each 211 category.

212 **Predicted effect of booster vaccination on stratified antibody dynamics**

213 Several studies have reported that booster doses after the primary two-dose vaccination rapidly increase antibody titers to a high level, and that these booster-elicited antibody responses 214 induce substantial neutralization against VOCs, including the Omicron variant¹⁵⁻¹⁷. However, it 215 remains unclear how booster vaccinations shape the induction of antibody response depending 216 217 on the second-dose, vaccine-elicited antibody dynamics (i.e., the time-dependent vaccine-elicited antibody history). Despite the current limited vaccine supply and large variation even within the 218 same stratified group, the priority for booster vaccines at the "individual level" of immunity and the 219 220 effect of boosters on "population-level" immunity are not well understood.

Assuming similar immune kinetics of the second-dose, vaccine-elicited antibody 221 dynamics, we modeled the elicited antibody responses on each group over the first year after the 222 booster vaccination at 8 months after the first vaccination (Fig 4A). Consistent with the current 223 booster vaccination studies^{13,14,16-20,27}, our simulations showed a rapid and high induction of 224 antibody responses regardless of group. Moreover, our simulation supported that a third-dose 225 226 vaccination booster protects against VOCs in a wide range of populations. In contrast, 35% and 9% of G5 and G6, respectively, at 1 month after booster vaccination showed limited induction (i.e., 227 less than 200 AU/mL) (see Fig 4B). We also confirmed a similar trend for booster vaccination at 228 229 1 year (Extended Data Fig 4A), and at the threshold of 80 AU/mL at 8 months (Supplementary **Fig 1B**). The existence of these vulnerable populations may explain the considerable variability 230 231 in booster-elicited antibody responses observed in several cohort studies^{6-8,15}. Targeting individuals in G5/G6 for booster vaccination is expected to provide protection from breakthrough 232 infection. 233

234 Next, taking advantage of our stratification, we further evaluated the effect of booster 235 vaccination on population-level immunity. Here we assumed a hypothetical cohort of 10,000 236 individuals, adjusted for age and sex distributions according to population estimates in Japan as 237 of 1 July 2021 by the Statistics Bureau of Japan, Ministry of Internal Affairs and Communications²⁸

(Fig 4C). We excluded populations aged less than 12 years in our simulations to reflect the age
 threshold of the cohort.

First, we simulated the fraction of individuals with antibody titers below the thresholds (i.e., 240 241 10 and 200 AU/mL) when all individuals received a booster vaccine (i.e., 100% booster coverage) at different time periods (8 and 12 months after the first vaccination) in **Extended Data Fig 4BC**. 242 243 As expected, 100% booster coverage effectively increases and recovers their immune responses 244 regardless of timing compared with the no booster scenario. Since 100% booster coverage is too optimistic given the limited vaccine supply, we next applied more realistic booster strategies: 20% 245 246 and 50% coverage of booster vaccinations (Fig 4DE and Extended Data Fig 4DE). We compared the booster vaccinations to 2,000 individuals (i.e., 20% of the total 10,000 population: 20% booster 247 vaccination) in G1/G2 (green curve: the durable population and others). G5/G6 (red curve: the 248 vulnerable population), and randomly sampled groups (blue curve) in Fig 4DE. Although small 249 differences were observed for the fraction with the threshold of 200 AU/mL (Fig 4D), the booster 250 vaccinations provided similar benefit to population-level immunity regardless of population 251 clusters. Similar trends in 50% booster coverage are shown in **Extended Data Fig 4DE**. Here we 252 253 again stress that the same conclusions are obtained with different thresholds instead of 200 254 AU/mL (e.g., **Supplementary Fig 1CDE** for 80 AU/mL). Considering the relative benefit of booster 255 vaccinations at the individual level, our identified vulnerable population is a candidate for priority booster vaccination under the limited vaccine supply (see **Discussion**). 256

257



Figure 4 | Simulating booster vaccines: (A) Predicted individual elicited antibody responses for 258 each group over the first year after booster vaccination at 8 months after the first vaccination are 259 shown. The horizontal dashed and vertical dotted lines correspond to 200 and 10 AU/mL and at 260 180 and 240 days after the first vaccination, respectively. (B) Fraction of individuals with antibody 261 titers of <10, 10-200, and 200 < AU/mL in each group at 1 month after booster vaccination are 262 plotted as black, white, and group color, respectively, in pie charts. (C) Age and sex distributions 263 of a hypothetical cohort adjusted via population estimates in Japan are shown along with those 264 in the Fukushima vaccination cohort. (D) and (E) show the time-dependent fractions of individuals 265 with antibody titers above 200 and 10 AU/mL with (i.e., colored curves) and without (i.e., black 266 dashed curve) 20% booster vaccination at 240 days after the first vaccination, respectively. The 267 green, blue, and red curves correspond to the booster vaccination targeting individuals randomly 268 269 sampled from G1/G2, G1-G6, and G5/G6, respectively. Enlarged view of the dotted box in (D) shows the fraction plotted in log-scale. 270

271 **Discussion**

As of May 6, 2022, there were 266 COVID-19 vaccine candidates undergoing phase 1/2 clinical trials and 124 candidates in phase 3 clinical trials (ClinicalTrials.gov). However, it is expected to take more time until second-generation vaccines that block transmission of Omicron and other novel virus variants with a much higher probability than current ones are available around the world. We still need to use the current first-generation vaccines as vaccine boosters. Therefore, determining the priority for booster vaccines in the vulnerable population is an important public health concern given a limited global supply of vaccines¹³⁻²⁰.

In this study, we aimed to understand the individual-level variation in vaccine-elicited immune responses at the time of booster vaccinations and the effect of booster vaccination. Only 1.07% of our cohort of individuals had a history of natural infection; thus, the influence of natural infection was minimal in the present study. We repeatedly assessed and monitored antibody titers following two doses of a SARS-CoV-2 vaccine in the unique Fukushima cohort of 2,526 individuals.

Previous studies generally investigated differences in vaccine-elicited antibody 285 responses after stratification of the population according to variables including age, sex, lifestyle 286 habits, comorbidities, adverse reactions, and medication use (i.e., in "given" groups). For example, 287 Levin and colleagues explored differences in antibody responses according to age, sex, and 288 289 immunesupression⁸. Ward and colleagues also showed that antibody responses are significantly decreased in individuals with diabetes, obesity, smoking habits, cancer, immunosuppression, or 290 neurological conditions after adjustment for age and sex²⁹. It is well known that active cytotoxic 291 292 chemotherapy and specific comorbidities such as kidney disease, hypertension, and heart disease significantly affect antibody responses^{22,30-32}. Importantly, in our cohort, we identified six 293 groups with different antibody responses by using a combined approach with process-based 294 295 mathematical modeling and data-driven analysis (i.e., without determining these "given" groups in advance as mentioned above). In particular, we found that G1 mainly consisted of participants 296 aged 0 to 39 years who were part of the durable population (i.e., those who were "rich" responders 297

showing high sustained antibody titers), whereas G5/G6 consisted of participants aged 65 to 100 years who were part of the vulnerable population (that is, those who were "poor" responders showing low sustained antibody titers). Our study showed that more than 10% of the durable population maintained their IgG(S) titers above 200 AU/mL for 1 year after the first vaccination, whereas approximately 50% of the vulnerable population could not maintain their antibody titers above 10 AU/mL after 1 year (i.e., they completely lost their vaccine efficacy).

An important question is how we maintain both individual- and population-level immunity 304 through booster vaccinations. Although T and B cell responses may contribute to protection from 305 symptomatic and severe infections^{4,12,27,33}, recent studies have shown that vaccine efficacy is 306 strongly linked to the elicited antibody responses, meaning that sustained high antibody titers 307 above a certain threshold are crucial^{2,3,34}. The present study showed that vulnerable populations 308 (i.e., G5/G6) include individuals who are not necessarily older adults nor with high-risk conditions. 309 In fact 5.5% of G5/G6 were young adults who did not have any underlying medical conditions but 310 reported at least one adverse reaction. Although there is no clear consensus for the threshold so 311 far, we found that individuals in G4 maintained high antibody titers induction for months, but their 312 titers rapidly decreased below 200 and 80 AU/mL around 6 and 7 months after the first dose on 313 314 average, respectively. Because individuals who are classified in G4, G5, and G6 represent those 315 with poor or rapidly decaying vaccine-elicited antibody responses who would not necessarily benefit from the current prioritized booster program on the basis of age and prior medical 316 317 conditions, it may be important to better understand the large variation in vaccine-induced immunity at the individual level as shown in the present study. Identifying these target individuals 318 319 and recruiting them to booster vaccinations are important tactics.

Most of the durable population (i.e., G1) will maintain their antibody titers induced by the second dose of mRNA vaccine at high levels at least for 8 months after the first dose, implying that the priority for booster vaccinations is low. Individuals in G1 had no history of natural infection except for one participant. In our study cohort, G1 made up only 5.7% of the cohort, and we only identified these participants because of the large participant size of the Fukushima cohort (over

2,500 individuals). In other words, if the cohort size was in the range of several hundreds, which is the usual size of prior studies made up of health care workers volunteers^{30,35-38} (e.g., 93.5% of 93 cohort studies in our literature review had less than 1,000 participants, see **Supplementary Note 1**), these durable individuals might not have been identified and might have been overlooked as outliers (e.g., around 5 individuals in a cohort of 100 individuals). Although the representativeness of the small cohort is unclear (only 61 individuals), preexisting high antibody titers before booster vaccination may limit the extent of antibody boosting (see below)¹⁵.

Our study suggests that booster vaccination of the vulnerable populations of G5/G6 at 80 days after the first vaccination increases antibody titers at both the individual and population level. Booster vaccinations added similar effects to population-level immunity regardless of a population profile under the limited vaccine supply (i.e., 20% and 50% booster coverage) in our simulations. These scenario-based simulations provide novel insights on the timing for booster vaccinations to maintain both individual- and population-level immunity against the emerging and future VOCs.

Overall, our analysis showed a large variation in vaccine-elicited antibody response at the 338 individual level⁶⁻⁸. Additional work is required to evaluate how specific antibody neutralizations of 339 VOCs, as quantified by live virus, influence the stratification^{13,15,27}, and how vaccine-elicited 340 cellular immunity, including B and T cell responses, would explain such variations^{12,15}. In particular, 341 342 we used only the basic demographic information for the characterization of the six groups and are currently collecting additional longitudinal immunologic information, such as cellular immune 343 344 changes (e.g., memory B cell compartments) and cytokine and chemokine profiles of the vaccinated individuals in our cohort. This will enable us to test and further characterize and 345 understand durability and vulnerability in G1 and G5/G6, respectively¹⁵. 346

There is an assumption in our mathematical model underlying the vaccine-elicited antibody response: antibodies are simply assumed to be generated from one compartment of B cells including heterogeneous cell populations that produce antibodies. That is, our mathematical model describes the vaccine-elicited antibody responses induced by the average B cell populations. As additional datasets become available on time course and quantitative phenotypic

352 B cell populations such as short-lived antibody-secreting cells (i.e., plasmablasts), long-lived antibody-secreting cells (i.e., plasma cells), and SARS-CoV-2-specific (class-switched) memory 353 B cells,^{9,39} it will be necessary to adjust our mathematical model to more precisely differentiate 354 the antibody dynamics of different B cells. In a recent study with a small sample size, the decay 355 rate of S-specific IgG from its peak to around 6 months after the first dose was similar, but the 356 average decay slowed between 6 and 9 months¹⁵. Other studies suggest that germinal center B 357 cell responses are critical to maintain the longevity of sustained antibody titers apart from the 358 quick and large antibody production immediately after the second vaccination (or infection)⁴⁰⁻⁴². 359 Although this emerging evidence for the heterogeneity of B cell populations implies that the two-360 compartment model of antibody-secreting cells (i.e., plasmablasts and plasma cells) may better 361 describe IgG(S) dynamics, our mathematical model describes the IgG(S) dynamics of 2,159 362 individuals (of which 208 individuals had 3 samples collected) at least until around 9 months after 363 the first dose. Our stratification is based on feature engineering but not reconstructed antibody 364 dynamics directly, meaning that the effect of the late-phase dynamics is minimal. However, long-365 term prediction of antibody dynamics by use of our mathematical model will not be possible. 366

Important research questions remain: whether people will be classified into the same (or 367 similar) stratified groups after booster vaccination, how the booster vaccine-elicited antibody 368 369 response will change depending on the interval between the second and third doses, and which group shows low and high neutralization to (emerging) VOCs, for example. The Fukushima cohort 370 is an ideal environment in which to evaluate how immunity, including humoral and cellular 371 responses of durable and vulnerable individuals, is increased by future SARS-CoV-2 infections 372 after the booster vaccination. Taking advantage of our Fukushima cohort, we will further evaluate 373 the impact of booster vaccinations and post-vaccination infections on the identified vulnerable 374 populations^{43,44}. 375

376 **METHODS**

377 Ethics statement

The study was approved by the ethics committees of Hirata Central Hospital (number 2021-0611-1) and Fukushima Medical University School of Medicine (number 2021-116). Written informed consent was obtained from all participants individually before the survey.

381

382 Participant recruitment and sample collection

The candidates were mainly recruited from Hirata village, Soma city, and Minamisoma 383 city in rural Fukushima prefecture. We conducted sequential blood sampling and non-sequential 384 blood sampling. Twelve health care workers participated in the sequential blood sampling, and 385 386 their vaccination and blood sampling schedule are shown in Fig 1E. A total of 2526 individuals participated in non-sequential blood sampling. Health care workers, frontline workers, and 387 administrative officers from each municipality were intentionally recruited to keep the cohort size 388 389 large and the dropout rate low. Although most of the health care workers, frontline workers, and 390 administrative officers were under the age of 65, relatively healthy community-dwelling older 391 adults living in the community and in long-term care facilities were also recruited to maintain a wide age range for the cohort. Blood sampling was performed once during each period in June, 392 393 September, and November 2021, respectively. The first vaccine dose was administered between 394 March 10 and August 20, 2021, and the second dose between March 31 and September 14. The median (interguartile range) interval for the two-dose vaccination was 21 days. A total of 226 395 396 health care workers participated in the first blood sampling between May 31 and June 6, 2021. A 397 total of 2526 individuals participated in the second blood sampling between September 8 and 398 October 8, 2021. A total of 2443 individuals participated in third blood sampling between November 21 and December 25, 2021 (Fig 1E). Note that the 12 health care workers (described 399 400 in Extended Data Fig 5B) with sequential blood sampling were not included in the non-sequential population of 2526 participants. In conclusion, of the total 2526 participants, those eligible for 401 analysis were those who completed the second vaccination and at least two blood samplings. 402 21

Participants whose antibody titer was higher than in the previous blood sampling in non-sequential
blood sampling were excluded from the final analysis (Fig 1B).

Information on sex, age, daily medication, medical history, date of vaccination, adverse reaction after vaccination, type of vaccination, blood type, bacillus Calmette–Guérin (BCG) vaccine history, smoking habit, and drinking habit was retrieved from the paper-based questionnaire (summarized in **Extended Data Table 1**). All blood sampling was performed at the medical facilities with 8 mL, and serum samples were sent to The University of Tokyo.

410

411 SARS-CoV-2-specific antibody measurement

All serological assays were conducted at The University of Tokyo. Specific IgG (i.e., 412 IgG(S)) and neutralizing activity were measured as the humoral immune status after COVID-19 413 vaccination. Specific IgG antibody titers (IgG(N)) were used to determine past COVID-19 infection 414 status. Chemiluminescent immunoassay with iFlash 3000 (YHLO Biotech, Shenzhen, China) and 415 416 iFlash-2019-nCoV series (YHLO Biotech, Shenzhen, China) reagents were used in the present study. The threshold value was 10 AU/mL. The measurement range was 2-3500 AU/mL for IgG(S) 417 418 and 4-800 AU/mL for neutralizing activity. For neutralizing activity, AU/mL×2.4 was used to 419 convert to International Units (IU/mL); for IgG(S), AU/mL×1.0 was used to convert to binding antibody units (BAU/mL). The testing process was as per the official guideline. Quality checks 420 421 were conducted every day before starting the measurement.

422

423 Mathematical modeling of (booster) vaccine-elicited antibody dynamics

424 We developed a simple but quantitative mathematical model describing the vaccine-425 elicited antibody dynamics as follows:

426
$$\frac{dM_{i}(t)}{dt} = \begin{cases} 0 & (t < \tau_{i}) \\ -dM_{i}(t) & (t \ge \tau_{i})' \end{cases}$$
(1)

427
$$\frac{dB(t)}{dt} = P_i(t)\frac{M(t)^m}{K^m + M(t)^m} - \mu B(t), \qquad (2)$$

428
$$\frac{dA(t)}{dt} = pB(t) - cA(t), \qquad (3)$$

where the variables $M_i(t)$, B(t), and A(t) are the amount of mRNA inoculated by the *i*-th vaccination, the number of antibody-secreting cells, and the antibody titers at time *t*, respectively. Parameters τ_i and *d* represent the timing of the *i*-th vaccination and the decay rate of mRNA. Note that $\tau_1 = 0$ is assumed for all individuals and $\tau_2 - \tau_1$ corresponds to the interval of the first and second vaccinations. We here considered that D_i is the inoculated dose of mRNA by the *i*th vaccination, that is, $M_i(\tau_i) = D_i$ for i = 1, 2, ..., n, and $M(t) = \sum_{i=1}^n M_i(t)$.

435 In our mathematical model, one compartment of B cells including heterogeneous cell 436 populations that produce antibodies is assumed, and therefore the product of $P_i(t)$ and $M(t)^m/(M(t)^m + K^m)$ represents the average *de novo* induction of the antibody-secreting cells, 437 438 that is, the average B cell population dynamics is modeled. Here $P_i(t)$ is a step function defined as $P_i(t) = P_i$ for $\tau_i + \eta_i \le t < \tau_{i+1} + \eta_{i+1}$, where η_i is the delay of induction of the antibody-439 secreting cells after the *i*-th vaccination: otherwise $P_i(t) = 0$. The parameters *m*, *K*, and μ 440 441 correspond to the steepness at which the induction increases with increasing amounts of mRNA (i.e., the hill coefficient), the amount of mRNA satisfying $P_i/2$, and the average decay rate of the 442 443 antibody-secreting cell compartment, respectively.

For example, after the first vaccination, antigen-specific B cells expand and induce 444 antibody-secreting cells and memory B cells. This rapid immune response regarding expansion 445 and induction is formulated by the function of $P_1M_1(t)^m/(M_1(t)^m + K^m)$ for $\eta_1 \le t < \tau_2$. On the 446 other hand, after the second vaccination, the memory B cells are reactivated by re-exposure to 447 448 antigen, and this reactivation induces antibody-secreting cells, increases the number of memory 449 B cells, and further re-establishes B cell memory. The recall B cell responses and their antibody secretion are described by the function of $P_2(M_1(t) + M_2(t))^m / ((M_1(t) + M_2(t))^m + K^m)$ for 450 $\tau_2 + \eta_2 \leq t$. The quantity and quality of memory B cells established by the second vaccination are 451 considered in P₂. In a similar manner, the recall B cell responses by the vaccine booster (i.e., the 452 third dose) are simply described by $P_3(M_1(t) + M_2(t) + M_3(t))^m / ((M_1(t) + M_2(t) + M_3(t))^m +$ 453

454 K^m) for $\tau_3 + \eta_3 \le t$. Note that $P_2 = P_3$, $\eta_2 = \eta_3$ are assumed in our booster simulations. The 455 other parameters, p and c, represent the antibody production rate and the clearance rate of 456 antibodies, respectively.

Since the clearance rate of antibody is much larger than the decay of antibody-secreting cells, we made a quasi-steady state assumption, dA(t)/dt = 0, and replaced Eq.(3) with A(t) = pB(t)/c. Thus, we obtained the following simplified mathematical model, which we used to analyze the antibody responses in this study (see **Extended Data Fig 5A**):

461
$$\frac{dM_i(t)}{dt} = \begin{cases} 0 & (t < \tau_i) \\ -dM_i(t) & (t \ge \tau_i)' \end{cases}$$
(4)

462
$$\frac{dA(t)}{dt} = H_i(t)\frac{M(t)^m}{K^m + M(t)^m} - \mu A(t),$$
(5)

463 where $H_i(t) = H_i = pP_i/c$ for $\tau_i + \eta_i \le t < \tau_{i+1} + \eta_{i+1}$. In our analysis, the variable A(t)464 corresponds to the IgG(S) titers (AU/mL).

465

466 **Quantifying vaccine-elicited time-course antibody dynamics**

In addition to the participants in the cohort, we included 12 health care workers whose 467 468 serum was sequentially sampled for 40 days (on average 25 samples per individual) for validation 469 and parameterization of a mathematical model for vaccine-elicited antibody dynamics. A nonlinear mixed effects model was used to fit the antibody dynamics model, given by Eqs.(4-5), 470 471 to the longitudinal antibody titers of IgG(S) obtained from the 12 health care workers. The mathematical model included both a fixed effect and a random effect in each parameter. That is, 472 the parameters for individual k, $\theta_k (= \theta \times e^{\pi_k})$, are represented as a product of θ (a fixed effect) 473 and e^{π_k} (a random effect). π_k follows a normal distribution with mean 0 and standard deviation 474 475 Ω . We here assumed that the parameters H_1, H_2, η_1, η_2 , and *m* varied across individuals, whereas we did not consider interindividual variability in other parameters to ensure parameter 476 identifiability. Note that the half-life of mRNA (i.e., $\log 2/d$) and dose of mRNA (i.e., D_i) are 477 assumed to be 1 day⁴⁵ and 100 $(\mu g/0.5 \text{mL})^{46}$, respectively. Fixed effect and random effect were 478

479 estimated by using the stochastic approximation expectation-approximation algorithm and empirical Bayes' method, respectively. Fitting was performed using MONOLIX 2019R2 480 (www.lixoft.com)⁴⁷. The estimated (fixed and individual) parameters are listed in **Supplementary** 481 482 Table 4. Interestingly, we found that most of the best-fitted estimated parameters in the mathematical model (i.e., D_1 , D_2 , d, μ , K, η_1 , η_2 , H_1) were the same or similar across the 12 483 individuals compared with those of parameters of m and H_2 (see **Supplementary Table 4**). We 484 485 note that m and H_2 , which showed wide variation of estimated values, contributed mainly to the 486 vaccine-elicited antibody dynamics after the second vaccination, whereas the other parameters 487 contributed to that after the first dose.

488 Since 2,407 participants had only 2 or 3 measurements of antibody titers at different time points, we hereafter fixed the parameters in our mathematical model to be the estimated 489 490 population parameters listed in **Supplementary Table 4**, except m and H_2 , to accurately 491 reconstruct the large variations in antibody dynamics after the second dose, and these two 492 parameters were independently estimated from each IgG(S) by a nonlinear least-squares method. Although the variation in the 12 individuals may not cover the whole variation of the antibody 493 494 induction dynamics after the first dose, our analysis focused on those after peak, and the results 495 on the stratification (in particular, the durable and vulnerable populations) are expected to be the same. Using the estimated parameters for each individual, we fully reconstructed the dynamics 496 of IgG(S) titers after the first vaccination (Extended Data Fig 5B). We summarized the distribution 497 498 of parameter values m and H_2 for 2,407 participants in **Extended Data Fig 5C**, and the best-fit 499 antibody titer curves of 600 randomly selected individuals are plotted along with the observed data for visualization in Supplementary Fig 2. 500

501

502 Unsupervised clustering and stratification of antibody dynamics

503 Unsupervised random forest clustering was performed on the selected features of the 504 vaccine-elicited time-course antibody dynamics (rfUtilities package in R). After a random forest 505 dissimilarity (i.e., the distance matrix between all pairs of samples) was obtained, it was visualized

with Uniform Manifold Approximation and Projection (UMAP) in a two-dimensional plane and was
 stratified with spectral clustering (Python scikit-learn). The optimal number of clusters was
 determined by the eigengap heuristic method.

509

510 Random forest classifiers for characterizing stratified groups

Random forest classifiers were trained to predict either of the six stratified groups (G1-G6) or their combination (G1/G2, G5/G6) using randomForest and rfPermute packages in R. The receiver operating characteristic (ROC) curve for each classifier was drawn from out-of-bag (OOB) samples using the pROC package in R. Feature importance was based on MeanDecreaseAccuracy and was shown as Chord diagrams (circlize package in R). Only the features with p < 0.05 (obtained with 1,000 permutations) were selected.

517

518 Statistical analysis

519 The paper-based questionnaires collected from 2,159 participants were converted into a set of categorical and numerical variables. Numerical variables included age and the interval 520 521 between the two doses. These variables were then used as input features to random forest 522 classifiers to predict each stratified group (G1-G6). Missing values of categorical variables were treated as a separate category and included in the analyses. The variables used here belonged 523 to any of the following five categories: (i) basic demographic information and lifestyle habits, (ii) 524 525 information on vaccinations. (iii) underlying medical conditions. (iv) adverse reactions, and (v) medications being taken. As a subanalysis, we also divided participants into three generations 526 according to age (0-39 [young], 40-64 [middle-aged], and 65-100 [old]) and trained random forest 527 classifiers in each generation. When necessary, the same variables were compared among 528 different generations or different groups using Pearson's chi-square test (for categorical variables), 529 530 analysis of variance (ANOVA, for more than two numerical variables), or Welch T-test (for two numerical variables). The Pearson correlation coefficient was calculated to evaluate the 531 association between a pair of continuous variables. To calculate the correlation matrix between 532

- 533 features, we augmented the variables by adding the following three categories to the above five
- 534 categories: (vi) antibody titers of each individual, (vii) dynamic parameters of each individual, and
- 535 (viii) dummy variables specifying each stratified group (G1 to G6). The correlation matrix of these
- 536 variables (features) was used as an input to principal component analysis. All statistical analyses
- 537 were performed using R (version 4.1.2).

538 LIST OF SUPPLEMENTARY MATERIALS

- **Supplementary Figure 1** | Sensitive analysis on different threshold of vaccine efficacy
- 540 Supplementary Figure 2 | Antibody titer trajectory for individual participants stratified into
- 541 different groups
- **Supplementary Table 1** | Details of query words and results
- **Supplementary Table 2** | Characteristic of previously reported cohorts
- **Supplementary Table 3** | Characteristic of vulnerable population
- **Supplementary Table 4** | Estimated fixed and individual parameters for 12 health care works
- **Supplementary Note 1** | Literature review
- **Supplementary Note 2** | Stratifying time-course pattern of antibody dynamics
- **Supplementary Note 3** | Inter-relationship of various features

550 **REFERENCES**

- Lumley, S. F. *et al.* Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care
 Workers. *N Engl J Med* 384, 533-540, doi:10.1056/NEJMoa2034545 (2021).
- 5532Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2554variants and the impact of boosting: a meta-analysis. Lancet Microbe 3, e52-e61,
- 555 doi:10.1016/S2666-5247(21)00267-6 (2022).
- 556 3 Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune protection from
 symptomatic SARS-CoV-2 infection. *Nat Med* 27, 1205-1211, doi:10.1038/s41591-021-01377-8
 (2021).
- Pegu, A. *et al.* Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. *Science* 373, 1372-1377, doi:10.1126/science.abj4176 (2021).
- 561 5 Gaebler, C. *et al.* Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**, 639-644, doi:10.1038/s41586-021-03207-w (2021).
- 563 6 Goldberg, Y. *et al.* Waning Immunity after the BNT162b2 Vaccine in Israel. *N Engl J Med* **385**, 664 e85, doi:10.1056/NEJMoa2114228 (2021).
- 565 7 Khoury, J. *et al.* COVID-19 vaccine Long term immune decline and breakthrough infections. 566 *Vaccine* **39**, 6984-6989, doi:10.1016/j.vaccine.2021.10.038 (2021).
- Levin, E. G. *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6
 Months. *N Engl J Med* 385, e84, doi:10.1056/NEJMoa2114583 (2021).
- Wheatley, A. K. *et al.* Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-*Nat Commun* 12, 1162, doi:10.1038/s41467-021-21444-5 (2021).
- 57110Cele, S. *et al.* Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.572Nature 602, 654-656, doi:10.1038/s41586-021-04387-1 (2022).
- Keehner, J. *et al.* Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System
 Workforce. *N Engl J Med* 385, 1330-1332, doi:10.1056/NEJMc2112981 (2021).
- 575 12 Kotaki, R. *et al.* SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two doses of 576 BNT162b2 mRNA vaccine. *Sci Immunol*, eabn8590, doi:10.1126/sciimmunol.abn8590 (2022).
- 577 13 Perez-Then, E. *et al.* Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron
 578 variants following heterologous CoronaVac plus BNT162b2 booster vaccination. *Nat Med* 28,
 579 481-485, doi:10.1038/s41591-022-01705-6 (2022).
- 580 14 Falsey, A. R. *et al.* SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. *N Engl J Med* 581 385, 1627-1629, doi:10.1056/NEJMc2113468 (2021).
- 58215Goel, R. R. et al. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-583CoV-2 mRNA vaccine. bioRxiv, doi:10.1101/2022.02.20.481163 (2022).
- 58416Muik, A. *et al.* Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited585human sera. Science 375, 678-680, doi:10.1126/science.abn7591 (2022).
- 58617Xia, H. *et al.* Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against587Omicron SARS-CoV-2. Cell Host Microbe, doi:10.1016/j.chom.2022.02.015 (2022).
- 58818Choi, A. et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in
healthy adults: an interim analysis. Nat Med 27, 2025-2031, doi:10.1038/s41591-021-01527-y
(2021).590(2021).
- 591 19 Juno, J. A. & Wheatley, A. K. Boosting immunity to COVID-19 vaccines. *Nat Med* 27, 1874 592 1875, doi:10.1038/s41591-021-01560-x (2021).
- 59320Shroff, R. T. *et al.* Immune responses to two and three doses of the BNT162b2 mRNA vaccine in594adults with solid tumors. *Nat Med* 27, 2002-2011, doi:10.1038/s41591-021-01542-z (2021).
- Wei, J. *et al.* Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general
 population of the United Kingdom. *Nat Microbiol* 6, 1140-1149, doi:10.1038/s41564-021-009473 (2021).
- Lustig, Y. *et al.* BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. *Lancet Respir Med* 9, 999-1009, doi:10.1016/S2213-2600(21)00220-4 (2021).

601	23	Kobashi, Y. et al. Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central
602		Fukushima, Japan: A historical cohort study. Int Immunopharmacol 98, 107884,
603		doi:10.1016/j.intimp.2021.107884 (2021).
604	24	Kobashi, Y. et al. The difference between IgM and IgG antibody prevalence in different
605		serological assays for COVID-19; lessons from the examination of healthcare workers. Int
606		Immunopharmacol 92, 107360, doi:10.1016/j.intimp.2020.107360 (2021).
607	25	Nakano, Y. et al. Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG
608		antibodies for symptomatic COVID-19 in Japan. Sci Rep 11, 2776, doi:10.1038/s41598-021-
609		82428-5 (2021).
610	26	Quantitative IgG antibodies to Spike protein of SARS-CoV-2,
611		<https: assets="" covqi_link-to-test-<="" departments="" files="" icahn.mssm.edu="" ismms="" pathology="" td=""></https:>
612		<u>Information-and-Interpretation.pdf</u> > (2020).
613	27	Lucas, C. et al. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.
614		Nature 600, 523-529, doi:10.1038/s41586-021-04085-y (2021).
615	28	Population Estimates by Age (Five-Year Groups) and Sex - July 1, 2021,
616		< <u>https://www.stat.go.jp/data/jinsui/pdf/202112.pdf</u> > (2021).
617	29	Ward, H. et al. Population antibody responses following COVID-19 vaccination in 212,102
618		individuals. Nat Commun 13, 907, doi:10.1038/s41467-022-28527-x (2022).
619	30	Yau, K. et al. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in
620		Patients Undergoing Hemodialysis. JAMA Netw Open 4, e2123622,
621		doi:10.1001/jamanetworkopen.2021.23622 (2021).
622	31	Moyon, Q. et al. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-
623		2 variants in systemic lupus erythematosus. Ann Rheum Dis 81, 575-583,
624		doi:10.1136/annrheumdis-2021-221097 (2022).
625	32	Shroff, R. T. et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in
626		adults with solid tumors. Nat Med 27, 2002-2011, doi:10.1038/s41591-021-01542-z (2021).
627	33	Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants
628		of concern. Science 374, abm0829, doi:10.1126/science.abm0829 (2021).
629	34	Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2
630		infection. Nat Med 27, 2032-2040, doi:10.1038/s41591-021-01540-1 (2021).
631	35	Costiniuk, C. T. et al. CTN 328: immunogenicity outcomes in people living with HIV in Canada
632		following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study.
633		BMJ Open 11, e054208, doi:10.1136/bmjopen-2021-054208 (2021).
634	36	Di Noia, V. et al. Rapid decline of humoral response to two doses of BNT162b2 vaccine in
635		patients with solid cancer after six months: The urgent need of the additional dose! Eur J Cancer
636		165 , 169-173, doi:10.1016/j.ejca.2022.01.011 (2022).
637	37	Fenioux, C. et al. SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in
638		Patients Treated With Anticancer Agents. JAMA Oncol, doi:10.1001/jamaoncol.2021.7777
639		(2022).
640	38	Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered
641		in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised,
642		controlled, phase 2/3 trial. Lancet 396 , 1979-1993, doi:10.1016/s0140-6736(20)32466-1 (2021).
643	39	Juno, J. A. et al. Humoral and circulating follicular helper T cell responses in recovered patients
644		with COVID-19. Nat Med 26, 1428-1434, doi:10.1038/s41591-020-0995-0 (2020).
645	40	Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre
646		responses. Nature 596, 109-113, doi:10.1038/s41586-021-03738-2 (2021).
647	41	Turner, J. S. et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in
648		humans. Nature 595, 421-425, doi:10.1038/s41586-021-03647-4 (2021).
649	42	Kim, W. et al. Germinal centre-driven maturation of B cell response to mRNA vaccination.
650		Nature 604, 141-145, doi:10.1038/s41586-022-04527-1 (2022).
651	43	Burki, T. K. Fourth dose of COVID-19 vaccines in Israel. Lancet Respir Med 10, e19,
652		doi:10.1016/S2213-2600(22)00010-8 (2022).

- Abbasi, J. Fourth COVID-19 Vaccine Dose Increases Low Antibodies. *JAMA* 327, 517, doi:10.1001/jama.2022.0727 (2022).
- Anand, P. & Stahel, V. P. Correction to: The safety of Covid-19 mRNA vaccines: a review.
 Patient Saf Surg 15, 22, doi:10.1186/s13037-021-00296-4 (2021).
- 46 Lin, D. Y. *et al.* Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. N
 658 Engl J Med 386, 933-941, doi:10.1056/NEJMoa2117128 (2022).
- 47 Traynard, P., Ayral, G., Twarogowska, M. & Chauvin, J. Efficient Pharmacokinetic Modeling
 660 Workflow With the MonolixSuite: A Case Study of Remifentanil. *CPT Pharmacometrics Syst*661 *Pharmacol* 9, 198-210, doi:10.1002/psp4.12500 (2020).
- 66248April 2021 Survey Population and Households by Municipality (Japanese Residents + Foreign663Residents)(Japanese), <<u>https://www.kokudo.or.jp/service/data/map/fukushima.pdf</u>> (2021).
- 664 49 The incidence of COVID-19 in Fukushima Prefecture (Japanese),
 665 (2021).
- 666
- 667

668 ACKNOWLEDGMENTS

669 We would like to thank all the staff from Fukushima Medical University, Seireikai health care group, Hirata village office, Soma City office, Soma Central Hospital, Soma General Hospital, 670 Minamisoma City office, Minamisoma City Medical Association, Minamisoma Municipal General 671 Hospital, Shindo Clinic and Medical Governance Institute, who contributed significantly to the 672 accomplishment of this research, especially, Ms. Yuka Harada, Ms. Serina Noji, Ms. Naomi Ito, 673 Dr. Makoto Kosaka, Mr. Anju Murayama, Mr. Sota Sugiura, Mr. Manato Tanaka, Ms. Yuna Uchi, 674 Mr. Yudai Kaneda, Mr. Masahiko Nihei, Mr. Hideo Sato, Ms. Rie Yanai, Ms. Yasuko Suzuki, Ms. 675 Keiko Abe, Dr. Hidekiyo Tachiya, Mr. Kouki Nakatsuka, Dr. Ryuzaburo Shineha, Ms. Miki Sato, 676 Dr. Masahiko Sato, Mr. Naoharu Tadano, Mr. Kazuo Momma, Mr. Shu-ichi Mori, Ms. Saori 677 Yoshisato, Ms. Katsuko Onoda, Mr. Satoshi Kowata, Mr. Masatsugu Tanaki, Dr. Tomoyoshi 678 Oikawa, Dr. Joji Shindo, Ms. Xujin Zhu, Ms. Asaka Saito, Ms. Yuumi Kondo, and Ms. Tomoyo 679 Nishimura. This study was supported by Medical & Biological Laboratories Co., Ltd., Shenzhen 680 681 YHLO Biotech Co., Ltd., the distributor and manufacturer of the antibody measurement system 682 (iFlash 3000), Research Center for Advanced Science and Technology in the University of Tokyo, and in part by a National Research Foundation of Korea (NRF) grant funded by the Korea 683 government (MSIT) (2022R1C1C2003637) (to K.S.K.); a Grant-in-Aid for JSPS Scientific 684 Research (KAKENHI) B 18H01139 (to S.I.), 16H04845 (to S.I.), Scientific Research in Innovative 685 686 Areas 20H05042 (to S.I.); AMED CREST 19gm1310002 (to S.I.); AMED Development of Vaccines for the Novel Coronavirus Disease, 21nf0101638s0201 (to S.I.), 21nf0101638h0001 (to 687 688 M.T.); AMED Japan Program for Infectious Diseases Research and Infrastructure, 689 20wm0325007h0001 (to S.I.), 20wm0325004s0201 (to S.I.), 20wm0325012s0301 (to S.I.), 690 20wm0325015s0301 (to S.I.); AMED Research Program on HIV/AIDS 22fk0410052s0401 (to S.I.); AMED Research Program on Emerging and Re-emerging Infectious Diseases 691 692 20fk0108140s0801 (to S.I.); AMED Program for Basic and Clinical Research on Hepatitis 21fk0210094 (to S.I.); AMED Program on the Innovative Development and the Application of New 693 Drugs for Hepatitis B 22fk0310504h0501 (to S.I.); AMED Strategic Research Program for Brain 694 32

Sciences 22wm0425011s0302; AMED JP22dm0307009 (to K.A.); JST MIRAI JPMJMI22G1 (to
S.I.); Moonshot R&D JPMJMS2021 (to K.A. and S.I.) and JPMJMS2025 (to S.I.); Institute of AI
and Beyond at the University of Tokyo (to K.A.); Mitsui Life Social Welfare Foundation (to S.I.);
Shin-Nihon of Advanced Medical Research (to S.I.); Suzuken Memorial Foundation (to S.I.); Life
Science Foundation of Japan (to S.I.); SECOM Science and Technology Foundation (to S.I.); The
Japan Prize Foundation (to S.I.); Foundation of Kinoshita Memorial Enterprise (to S.I.); and Kowa
Co (to M.T.).

702

703 AUTHOR CONTRIBUTIONS

SI and MT designed the research. YKobashi, YS, TZ, YN, FO, MTa, CY, KS, and MTs conducted the data collection and curation. YT, MK, MY, TA, YS, SN, TK, AS, AN, YS and YKaneko carried out the investigations. NN, KSK, DT, MA, SIwanami, KA, and SI carried out the computational analysis. SI and MT supervised the project. All authors contributed to writing the manuscript.

709

710 COMPETING FINANCIAL INTERESTS

YKaneko is employed by Medical & Biological Laboratories, Co. (MBL, Tokyo, Japan). MBL imported the testing material used in this research. YKaneko participated in the testing process; however, he did not engage in the research design and analysis. YKobashi and MT received a research grant from Pfizer Health Research Foundation for research not associated with this work.

716

717 INSTITUTIONAL REVIEW BOARD STATEMENT

This study was approved by the ethics committees of Hirata Central Hospital (number 2021-0611-1) and Fukushima Medical University (number 2021-116). This study was conducted in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki).

721

722 INFORMED CONSENT STATEMENT

723 Informed consent was obtained from all subjects involved in the study.

725 EXTENDED DATA FIGURES



Extended Data Figure 1 | Comparison between IgG(S) and neutralization activity: (A) Curve with IgG(S) and neutralization activity on the Y-axis and its corresponding neutralization activity rank on the X-axis are plotted in black and gray, respectively. (B) Correlations between IgG(S) and neutralization activity from same samples are described. Data points represent individual samples. Correlations were calculated as Pearson correlation coefficients.



Extended Data Figure 2 | Clustering vaccine-elicited antibody response: (A) UMAP of 10 731 732 clustered antibody responses based on the extracted features from the reconstructed individual-733 level antibody dynamics are shown. Data points represent individual participants and are colored by the 10 clusters (i.e., C1 to C10). (B) Reconstructed individual antibody dynamics after 25 days 734 735 after the first vaccination in each cluster in the different colors are represented along with the measured IgG(S). The black and red circles correspond to individuals who had 2 or 3 736 737 measurements of antibody titers at different time points, respectively. (C) The difference in 738 antibody titers between the two measurements and its sampling interval are compared among 739 clusters. (D) Reconstructed individual antibody dynamics after 25 days after the first vaccination 740 in each group in the different colors are represented along with the measured IgG(S) in black and 741 red corresponding to individuals who had 2 or 3 measurements, respectively. The red curves 742 indicate individuals who were infected with SARS-CoV-2 or whose family was infected. The 743 horizontal dashed lines correspond to 200 and 10 AU/mL, respectively.



Extended Data Figure 3 | Characterization of stratification: (A) and (B) The ROC curves of random forest classifiers trained on predicting G3, G4, or G5/G6 in young, middle-aged, and old populations are shown, respectively. The corresponding AUC value of each ROC curve is calculated on the top of each panel. (C) Name labels of Figure 3D (principal component analysis of features) are shown.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.11.22276266; this version posted June 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.



Extended Data Figure 4 | Simulating booster vaccines under different scenarios: (A) 749 Predicted individual elicited antibody responses in each group over the first year after the booster 750 vaccination at 1 year after the first vaccination are shown. The horizontal dashed and vertical 751 dotted lines correspond to 200 and 10 AU/mL and at 180 and 240 days after the first vaccination, 752 753 respectively. (B) and (C) show the fractions of individuals with antibody titers above 200 and 10 AU/mL with (i.e., colored curves) and without (i.e., black dashed curve) 100% booster vaccination 754 at 240 and 365 days after the first vaccination, respectively. (D) and (E) show those above 200 755 and 10 AU/mL with and without 50% booster vaccination at 240 days after the first vaccination, 756 respectively. The green, blue, and red curves correspond to the booster vaccination targeting 757 individuals randomly sampled from "in addition G1/G2, extra are from G1-G6", "G1-G6", and "in 758 759 addition G5/G6, extra are from G1-G6", respectively.



760 Extended Data Figure 5 | Quantification of vaccine-elicited antibody dynamics: (A) Schematic diagram of mathematical modeling. (B) Observed and fitted IgG(S) titers for individual 761 participants are described. The IgG(S) titers are obtained from the 12 health care workers with 762 sequentially sampled serum for 40 days (on average 25 samples per individual). Enlarged view 763 764 of the dotted box shows a fine-level plot focusing on the early period. The dashed vertical lines at day 21 correspond to the date of second vaccination. (C) Distributions of estimated parameter 765 766 values of H_2 and m for 2,407 participants are plotted, respectively, among total or stratified 767 populations. (D) Distributions of the extracted features from the reconstructed individual-level antibody dynamics are plotted, respectively, among total or stratified populations. 768

769 Extended Data Table 1 | Basic demographics for the Fukushima vaccination cohort

Characteristic	<40 years	40-64 years	>65 years	Overall	p-value
Gender					0.001
Male	338(46.8)	421(38.2)	286(40.8)	1045(41.4)	
Vaccine type					0.015
BNT162b2(Pfizer-BioNTech)	651(90.0)	971(88.1)	649(92.6)	2271(89.9)	
mRNA-1273(Moderna)	0(0.0)	3(0.3)	0(0.0)	3(0.1)	
Days (mean [SD])					
from 1st dose	106.3[37.7]	104.4[35.1]	103.8[17.2]	104.8[32.0]	0.302
from 2nd dose	181.4[37.5]	180.1[35.7]	180.1[16.9]	180.5[32.2]	0.292
Blood type					
A	239(35.7)	427(39.0)	212(35.4)	878(37.2)	<0.001
В	151(22.6)	236(21.6)	140(23.4)	527(22.3)	<0.001
0	213(31.8)	326(29.8)	172(28.7)	711(30.1)	0.367
AB	66(9.9)	105(9.6)	75(12.5)	246(10.4)	0.432
BCG history	560(83.5)	907(83.1)	412(61.9)	1879(77.4)	0.395
Smoking	144(19.9)	253(23.0)	63(9.0)	460(18.2)	<0.001
Drinking habits					<0.001
Almost not	403(55.7)	542(49.2)	458(65.3)	1403(55.5)	
Occasionally	247(34.2)	310(28.1)	90(12.8)	647(25.6)	
Everyday	63(8.7)	222(20.2)	127(18.1)	412(16.3)	
Daily Alcohol Consumption					<0.001
<20g	322(44.5)	382(34.7)	176(25.1)	880(34.8)	
20-40g	108(14.9)	214(19.4)	87(12.4)	409(16.2)	
40-60g	20(2.8)	60(5.4)	20(2.9)	100(4.0)	
>60g	5(0.7)	13(1.2)	2(0.3)	20(0.8)	
Comorbidities					
Hypertension	8(1.1)	237(21.5)	432(61.6)	677(26.8)	<0.001
Dyslipidemia	12(1.7)	123(11.2)	146(20.8)	281(11.1)	<0.001
Heart disease	14(1.9)	47(4.3)	140(20.0)	201(8.0)	<0.001
Diabetes	6(0.8)	72(6.5)	110(15.7)	188(7.4)	<0.001
Allergic disease	69(9.5)	95(8.6)	21(3.0)	185(7.3)	<0.001
Asthma	49(6.8)	45(4.1)	28(4.0)	122(4.8)	0.079
Liver disease	11(1.5)	45(4.1)	58(8.3)	114(4.5)	<0.001
Cancer	3(0.4)	35(3.2)	46(6.6)	84(3.3)	<0.001
Gout	5(0.7)	45(4.1)	26(3.7)	76(3.0)	0.001
Thyroid disease	8(1.1)	40(3.6)	11(1.6)	59(2.3)	0.005
Lung disease	12(1.7)	11(1.0)	28(4.0)	51(2.0)	<0.001
Mental disease	17(2.4)	16(1.5)	13(1.9)	46(1.8)	0.739
Rheumatism	2(0.3)	16(1.5)	19(2.7)	37(1.5)	0.006
Kidney disease	6(0.8)	7(0.6)	14(2.0)	27(1.1)	0.089
Anaphylaxis	6(0.8)	7(0.6)	5(0.7)	18(0.7)	0.994
	4(0.6)	6(0.5)	5(0.7)	15(0.6)	0.993
	4(0.6)	5(0.5)	1(0.1)	10(0.4)	0.793
COVID-19	U(U.U)	3(U.3)	4(U.6)	7 (U.3)	0.38
Othere	∠(U.3) 51/7 1)	4(U.4)	U(U.U)	O(U.Z)	0.004
Drug	51(7.1)	147(13.3)	169(27.0)	367(15.3)	<0.001
Storoid	0(4.0)	00/0 4)	06/0 7\	EQ(0.0)	0.000
	9(1.∠) 21/4 2)	Z3(Z.1) 70(7 4)	20(3.1) 20(11 7)	JO(∠.J)	0.002
NOAIDS Acotominochan	31(4.3) 0/1 4)	10(1.1)	0∠(11./) 20(4.2)	191(7.0)	
Acetaminophen	0(1.1)	ZZ(Z.U)	JU(4.3)	OU(2.4)	NU.UU I
	40(0.4) 6/0.9)	00(0.9)	43(0.1) 9(1.1)	104(0.1) 24(1.0)	0.307
mmunosuppressants	0(0.8)	10(0.9)	0(1.1)	Z4(1.0)	0.432

Biologics	2(0.3)	5(0.5)	4(0.6)	11(0.4)	0.395
Anti-cancer agent	0(0.0)	5(0.5)	5(0.7)	10(0.4)	0.292
Adverse Reaction					
Local pain	515(71.2)	684(62.1)	228(32.5)	1427(56.5)	<0.001
Fatigue	511(70.7)	627(56.9)	119(17.0)	1257(49.8)	<0.001
Joint pain	327(45.2)	354(32.1)	90(2.8)	771(30.5)	<0.001
Fever (over 37.5 degree)	370(51.2)	308(28.0)	41(5.9)	719(28.5)	<0.001
Headache	321(44.4)	331(30.0)	34(4.9)	686(27.2)	<0.001
Fever (under 37.5 degree)	137(19.0)	209(19.0)	40(5.7)	386(15.3)	<0.001
Dizziness	57(7.9)	45(4.1)	9(1.3)	111(4.4)	<0.001
Nausea	51(7.1)	41(3.7)	6(0.9)	98(3.9)	<0.001
Diarrhea	30(4.2)	25(2.3)	3(0.4)	58(2.3)	<0.001
Others	40(5.5)	69(6.3)	16(2.3)	125(5.0)	0.003

Supplementary Information

Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan

Naotoshi Nakamura^{1,†}, Yurie Kobashi^{2,3,†}, Kwang Su Kim^{1,4,5,†}, Yuta Tani⁶, Yuzo Shimazu², Tianchen Zhao², Yoshitaka Nishikawa³, Fumiya Omata³, Moe Kawashima², Makoto Yoshida⁶, Toshiki Abe², Yoshika Saito⁶, Yuki Senoo⁶, Saori Nonaka², Morihito Takita², Chika Yamamoto², Takeshi Kawamura^{7,8}, Akira Sugiyama⁷, Aya Nakayama⁷, Yudai Kaneko^{8,9}, Hyeongki Park¹, Yong Dam Jeong^{1,5}, Daiki Tatematsu¹, Marwa Akao¹, Yoshitaka Sato¹⁰, Shoya Iwanami¹, Yasuhisa Fujita¹, Masatoshi Wakui¹¹, Kazuyuki Aihara¹², Tatsuhiko Kodama⁸, Kenji Shibuya^{13,14}, Shingo Iwami^{1,16,17,18,19,20,‡,*} and Masaharu Tsubokura^{2,3,6,20,‡,}

¹interdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan.²Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan. ³Department of General Internal Medicine, Hirata Central Hospital, Fukushima, Japan. ⁴Department of Science System Simulation, Pukyong National University, Busan, South Korea. ⁵Department of Mathematics, Pusan National University, Busan, South Korea. ⁶Medical Governance Research Institute, Tokyo, Japan. ⁷Proteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo, Japan. ⁸Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. ⁹Medical & Biological Laboratories Co., Ltd, Tokyo, Japan. ¹⁰Department of Virology, Nagoya University Graduate School of Medicine, Nagoya, Japan. ¹¹Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.¹²International Research Center for Neurointelligence, The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Tokyo, Japan. ¹³Soma Medical Center of vaccination for COVID-19, Fukushima, Japan.¹⁴Tokyo Foundation for Policy Research, Tokyo, Japan. ¹⁵Institute of Mathematics for Industry, Kyushu University, Fukuoka, Japan. ¹⁶Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto, Japan. ¹⁷Interdisciplinary Theoretical and Mathematical Sciences Program (iTHEMS), RIKEN, Saitama, Japan. ¹⁸NEXT-Ganken Program, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan. ¹⁹Science Groove Inc., Fukuoka, Japan. ²⁰Minamisoma Municipal General Hospital, Fukushima, Japan.



Supplementary Figure 1. Sensitivity analysis on different thresholds of vaccine efficacy: (A) and (B) show the fractions of individuals with antibody titers of <10, 10-80, and 80 < AU/mL in each group at 180, 240, and 365 days after the first vaccination and at 1 month post-booster vaccination plotted as black, white, and group color, respectively (for 200 AU/mL, corresponding to Fig 2H and Fig 4B). (C), (D), and (E) represent the time-dependent fractions of individuals with antibody titers above 80 AU/mL with (i.e., colored curves) and without (i.e., black dashed curve) 100%, 50%, and 20% booster vaccination, respectively, similar to Extended Data Fig 4B, Fig 4D and Extended Data Fig 4D for 200 AU/mL of the threshold.

	Group1	8704 -		87704	4000 d	80004 -	80004 -	80004	8000 A -	87774 -
	36	37 3000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	51 500 000 000 000 000 000 000 000 000 0	64 2000 0 100 200 500						272 2000 2000 2000 2000 0 100 200 300
			302 300 100 0 100 20 300	3005 3000 100 100 100 100		321 3000 1000 0 100 200 300				501 0000 0 1000 000 000
	506 0000 0 100 200 300	518 5000 2000 0 100 200 300	525 525 1000 0 100 200 300	539 5000 5000 5000 0 100 200 300	542 542 0 100 200 200	545 2000 2000 2000 2000 2000 2000 2000 2	548 5000 5000 5000 5000 5000 5000 5000 5	8000 40000 2000 2000 2000 0 0 0 0 0 0 0 0	568 2000 2000 2000 2000 2000 2000 2000 20	578 000 0 100 200 300
	563	589 5000 1000 1000 1000 1000 1000 1000 100	5000 5000 5000 5000 5000 1000 0 100 200 ado	500 500 500 500 500 500 500 500 500 500	5000 5000 5000 5000 5000 5000 5000 500					632 632 632
	645 0 100 200 300			736 736	788 1000 1000 1000 1000 1000 1000 1000 1	5000 5000 1000 1000 0 100 200 300	839 1000 1000 1000 1000 1000 1000 1000 10	852 1000 1000 1000 1000 1000 1000 1000 10	882 1000 1000 1000 1000 0 100 200 300	896 3000 1000 0 100 200 300
	890 800 0 100 200 200	5000 3000 1000 1000 0 100 200 a00	8000 4000 1000 0 100 20 ado	914 914	940 940 1000 1000 1000 200 200	947 1000 1000 1000 1000 1000 1000 1000 10	954 3000 1000 1000 1000 1000 1000 1000 100	965 1000 1000 1000 1000 1000		964
		9000 9000 9000 9000 9000 904 904	9000 000 0000 0							
		9000 4000 1056 1056 1056 1056 1056 1056	1071 1000 1000 1000 1000 1000 1000 1000							
		1375	1377 1000 1000 1000 1000 1000 1000 1000				1450 1000 1000 1000 1000 1000 1000 1000		1491	
		1643 1000 1000 1000 1000 1000 1000 1000 10		1737 1000 0 100 200 300	1871 1000 0 100 200 300	1881 1000 1000 1000 1000 1000 1000 1000	1899 1000 1000 1000 1000 1000 1000 1000	1900 1000 1000 0 100 200 300	1915 1000 1000 1000 1000 1000 1000 1000	
		6000 5000 5000 5000 5000 40	5000 5000 5000 1000 1000	57	63 3000 3000 1000	68 3000 1000 1000	8000 1000 1000 1000 1000	0000 0000 0000 10000 10000 10000	8000 1000 1000 1000 1000 1000	8000 1000 1000 1000 1000 1000
	0000 0000 0000 0000 0000 0000 0000 0000 000	0000 100 200 300 2000 89 2000 89								
	0 100 200 300				0 100 200 300	0 100 200 200	6 100 200 300	6 100 200 300	0 100 200 300	0 100 200 a00
mL)										
(AU/										
lgG(S	348 3000 1000 100 200 300	359 7000 100 200 200 200					391 5 to zo zo zo			
				434	435	458	459	461	462 100 10 10 10 10	
	470 470 100 100 200 300	473		480	489 1000 0 100 200 300	493	507	523	533	579 579 0 100 200 300
	580 500 100 0 100 20 30	587 587 1000 0 100 200 300	588 5000 1000 0 100 200 300		621 0000 0 to zo zo	628			665 0 10 20 30	678 678
	691 5000 5000 5000 5000 5000 5000 5000 50	702 1000 1		720 1000 1000 1000 1000 1000 1000 1000 1	723		733	743	746 1000 1000 1000 1000 1000 1000 1000 10	751 1000 0 100 200 300
	Group3	9000 1 9000 1 29	9000 1 9000 1 30	9000 1 5000 1 4000 1 32	9000 - 5000 - 33	8000 1 5000 1 4000 1 34	5000 1 4000 - 38	6000 1 5000 1 4000 1 39	6000 1 5000 1 4000 1 41	0001 2000- 4000- 52
			2000 0 100 200 300 0000 1							
	533 5000 1000 0 100 200 300	54 2000 1000 0 100 200 200	56 2000 1000 0 100 200 300	60 2000 0 160 200 300	1000 1000 0 100 200 300 500	5000 5000 100 100 100 100 100 100	5000 2000 1000 0 100 200 300	5000 2000 1000 0 100 200 300	5000 2000 1000 0 100 200 300	5000- 77 1000- 1000- 0 100 200 300
	5000 4000 1000 1000 0 100 200 300	80 2000 1000 0 100 200 300	81 2000 0 100 200 300	83 1000 1000 1000 200 300	85 5000 - 85 2000 - 85 2000 - 100 2000 - 200 300	2000 2000 2000 0 100 200 300	90 5000 50	91 2000 1000 0 100 200 300	92 2000 1000 0 100 200 300	94 2000 1000 0 100 200 200
	95 3000 1000 1000 1000 1000 1000 1000 200 300	96 96 1000 1000 1000 1000 1000 1000 1000	96 9000 1000 1000 1000 1000 1000 1000 10	999 1000 1000 0 100 200 300	101 2000 1000 0 100 200 300		5000 40000 1000 0 100 200 300			
	113 1000 1000 1000 1000 1000 200 300	114 2000 1000 0 100 200 300	116 2000 1000 0 1000 0 100000000	118 1000 1000 1000 1000 1000 1000 1000	5000 4000 119 2000 0 100 200 300	\$000 4000 1000 0 0 0 0 0 0 0 0 0 0 0 0 0	5000 4000 1000 0 1000 0 1000 1000 1000 2000 300	122 1000 1000 0 100 200 300	5000 4000 1000 0 100 200 500	
	130 130 1000 0 100 200 300	131 1000 0 100 200 300		134 2000 1000 0 100 200 300	136 100 100 100 100 100 100 100 10	9000 4000 1000 0 0 0 0 0 0 0 0 0 0 0 0 0		141 2000 1000 0 100 200 300	4000 4000 1000 0 0 0 0 0 0 0 0 0 0 0 0 0	
	5000 5000 1000 1000 0 100 200 300	152 1000 0 100 250 300	153 0000 0 100 250 300	154 2000 1000 0 160 200 300	155 1000 0 100 200 300	5000 5000 5000 156 5000 100 100 100 200 300	5000 5000 159 1000 0 0 0 100			
	165			168 1000 0 100 200 300	5000 4000 1000 0 100 200 300					
				181 2000 1000 0 160 260 300	8000 4000 1000 0 0 0 0 0 0 0 0 0 0 0 0 0	9000 4000 1000 1000 0 100 200 300				5000 5000 1000 0 100 200 500
	191 1000 1000 1000 1000 1000 1000 1000		197 1000 1000 1000 1000 1000 1000 1000 1	198 1000 1000 0 100 20 300	201 200 1000 0 100 200 300	202 202 1000 1000 1000 1000 1000 1000 1	203 2000 1000 0 100 200 300	204	205 2000 2000 2000 2000 2000 1000 1000 1	

Days after 1^{st} vaccination

	Group4	5000 4000 3000 4000 4000 4000	0000 1 5000 - 46 3000 - 46	59 59	0000 5000 3000 3000 5000 61	9000 5000 3000 3000 67	0000 0000 0000 0000 71	0000 5000- 3000- 3000- 84	0000 5000 3000 3000 3000 110	8000 4000 4000 117
	1000 50 100 150 200 250 50000 40000 127	1000 50 100 150 250 250	1000 100 100 150 200 250 100	1000 50 100 150 200 250 5000 5000 150	0000 60 100 150 200 250	0000 <u>sb</u> 100 150 200 250 0000 0000 0000 0000 218	1000 50 100 150 200 250	0000 <u>s0</u> 100 100 200 250 0000 0000 0000 0000 0000 0000 0000 0	1000 50 100 100 200 200	
										2000 50 100 150 200 250
	2000 1000 50 100 150 200 250			2000 2000 50 100 150 200 250	2000 1000 500 100 150 200 250			3000 1000 50 100 150 200 250		
	289 2000 2000 2000 2000 2000 2000 2000 2	293 1000 50 100 150 200 200	294 1000 50 100 150 200 250	306 3000 1000 60 160 160 260 280	318 3000 1000 50 100 150 200 250	322 1000 1000 1000 1000 1000 1000 100 100 200	325 1000 1000 1000 1000 1000 1000 1000 10	337 3000 50 100 120 200 250	360 360 50 160 160 200 280	363 3000 3000 3000 3000 3000 3000 3000
	365 2000 50 10 150 20 250	370 3000 1000 5000 500 150 260 250	376 2000 50 100 150 200 250	390 3000 1000 1000 1000 1000 1000 1000 1	9000- 4000- 2000- 1000 50 100 150 200 250	409 2000 1000 50 100 150 200 250	412 4000 1000 1000 1000 1000 1000 1000 1	416 4000 2000 500 500 500 500 500 160 160 200 250	5000 2000 1000 50 100 160 200 280	5000 3000 1000 50 100 100 200 250
	424 4000 4000 50 100 150 200 250	432 4000 1000 50 100 150 250 250	451 2000 1000 50 100 150 200 250	454 5000 1000 50 100 150 200 250	465 3000 1000 50 tõo tšo zõo zšo	472 4000 1000 50 100 150 200 250	484 5000 5000 5000 5000 5000 5000 5000 5	679 5000 1000 500 100 150 200 250	698 2000 2000 2000 50 100 150 200 250	5000 4000 500 150 200 250
	5000 5000 1000 50 100 150 250 250	779 779 1000 1000 1000 150 200 250	851 5000 1000 5000 50000 50000 50000 50000 50000 50000 50000 50000 50000 50000 50000 50000 50000 50000 5000 5000000	911 9000 9000 9000 9000 9000 9000 9000	0000 0000 0000 0000 0000 0000 0000 0000 0000	1336 1000 1000 1000 1000 150 200 250	1348	1349 1000 1000 1000 1000 1000 150 200 250	1353 1000 1000 1000 1000 1000 1000 1000	1356 1000 1000 150 150 200 250
		1359 1000 100 100 19 200 200	1361 1361	1392	0000 0000 0000 0000 0000 0000 0000 0000 0000	0000 0000 0000 0000 0000 0000 0000 0000 0000	1495		1649 1000 1000 1000 100 100 100 200 250	1656 1000 1000 1000 100 100 100 200 250
	1659		1663	1670	8000 4000 1000 1000 1000	1698	1708	1713	1717 1700 1000 1000	1719
	50 100 150 200 250	60 100 150 200 250	80 100 150 200 250	00 100 100 200 200 0000 0000 0000 0000 0000 000 100 100 200 200	00 100 150 200 250	60 100 150 200 250	50 100 150 200 250	60 100 150 200 250	50 100 150 200 250	50 100 150 200 250
	Group5	8000 4 2000 - 2000 - 2000 - 2000 - 1000 -	0000 1 5000 1 4000 253 2000 1 2000 1 1000 1	0000 4 2000 - 0000 - 271 2000 -	8000 4 2000 - 3000 - 3000 - 2000 - 1000 -	0000 4 5000 - 4000 - 3000 - 2000 - 1000 -	9000 4 5000 - 4000 - 3000 - 1000 - 1000 -	8000 4 5000 - 4000 - 3000 - 2000 - 1000 -	8000 4 5000 - 4000 - 3000 - 2000 - 1000 -	8000 4 5000 - 4000 - 5000 - 5000 - 1000 -
	5000 5000 5000 5000 5000 5000 5224	5000 5000 5000 5000 5000 5000 5000 500	00001 50000 50000 50000 50000 50000 50000 50000 5000 5000 5000	9000 9000 9000 9000 9000 9000 9000 900	9000 1 900 100 150 200 250 9000 1 9000 1 9000 1 9000 1 900	0000 1 500 100 150 200 250 5000 1 5000 5555	9000 900 100 150 200 250 9000 9000 9000 9000 9000 9000 9000 9	500 100 150 200 250 5000 1 5000 1 5000 1 5000 1 500 575	500 100 150 200 250 5000 1 5000 1 5000 1 5000 1 5077 5000 1	5000 1 5000 1 500 1
	50001 50001 50001 50001 50001 5000 5000	00001 50000 50000 50000 50000 50000 50000 50000 50000 6005	5000 5000 5000 5000 5000 5000 612	50001 50000 5000 500 50000 50000 500000 50000 50000 50000 500000 50000 50000 50000 50000 5000	5000 5000 5000 5000 5000 5000 648 5000 5000 5000 648	50 100 150 200 250 50000 50000 50000 50000 50000 603	500 100 150 200 250 50000 50000 50000 50000 50000 5000 5000 500 150 200 250 606	5000 150 200 250 5000 150 200 250 5000 1 5000 1 5000 1 5000 1 500 1 500 1 50 1 50 1 50 1 50 1 50 1 50 1 50 2 50	5000 1 5000 1 5000 1 5000 1 5000 1 5000 1 5000 1 5000 1 5000 1 500 1 500 1 500 1 50 1 5	5000 1 5000 1 500 1 5
Ĺ	1000 50 100 150 200 250	1000 60 1/0 1/0 2/0 2/0 5000 5000 5000 5000 682	1000 1 60 100 150 260 250	1000 60 100 150 200 250 5000 3000 3000 3000 704	1000 60 100 150 200 250 5000 3000 3000 719	1000 60 100 150 200 250 5000 3000 3000 3000 724	1000 50 100 150 200 250 5000 3000 3000 3000 3000 3000 3000 3	1000 50 100 150 200 250 5000 4000 5000 4000 734	1000 50 160 160 260 250 5000 4000 4000 5000 4000 735	1000 50001 50001 40001 40001 742
AU/m	1000 50 100 150 200 250 5000 5000 5000 5000 5000 5000	1000 	0000 60 100 160 200 280	1000 60 100 150 200 250 5000 5000 5000 5000 784	1000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1000 60 100 150 200 250	1000 50 100 150 200 250	1000 500 100 100 200 250 5000 1 5000 1 5000 1 5000 1 5000 1 5000 1 840	1000 500 100 150 250 250 5000 1 5000 1 5000 1 5000 1 5000 1 843	1000 50 100 150 200 250
) (S)5	50000 50000 50000 50000 50000 80000 80000 80000 80000 80000 80000 80000 80000 80000 80000 80000 8000 8000 8000 8000 8000 8000 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800	2000 1000 50 100 150 200 250 5000 5000 60 100 150 200 250	2000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0000 0 100 150 200 250 0 100 150 200 250	2000 0 100 150 200 250 500 100 150 200 250	2000 50 100 150 200 250	0000 0 100 150 200 250 0 000 100 150 200 250	2000 50 100 150 200 250	2000 50 100 150 250 250	2000 1000 500 100 160 280 280 5000 4000 9035
lg(50000 1000 50 100 150 200 250	3000 1000 60 100 150 260 250	00001 0001 0001			3000 1000 60 100 150 200 250	3000 50 100 150 200 250			5000 1000 50 100 150 250 250
	5000 5000 50 100 150 200 210	942 1000 50 100 150 260 250	978 1000 50 100 150 200 250	905 1000 50 100 150 200 250	9000 1000 50 100 150 200 250 000001	992 3000 56 100 150 200 250	1047 1000 50 100 150 200 250	1052 1000 50 100 150 200 250	1004 1004 50 100 150 200 250	
		0000- 0000- 0000- 0000- 0000- 0000-1 000-1 00			1096 1000 1000 1000 1000 1000 100 100 100 1	1106 1000 1000 50 100 150 200 250		1117 1000 1000 1000 100 150 200 250	1198 1000 1000 50 100 150 200 250	1364 2000 1000 50 160 150 200 250
	2000 4000 1000 50 100 150 250 250	1386 1000 1000 1000 1000 1000 1000 1000 10	2000 4000 2000 1000 0 500 100 150 200 250		1410 1000 1000 1000 1000 1000 1000 1000	1411 3000 1000 500 100 150 200 250	1412 0000 0000 0000 0000 0000 0000 0000	1413 1000 1000 1000 1000 1000 1000 1000	4000 4000 1000 500 100 150 250 250	1419 1000 1000 1000 1000 1000 100 150 200 250
	5000 4000 5000 5000 5000 1423 1423 1423 5000 5000 1000 1000 100000 10000 10000 10000 10000 10000 10000	5000 4000 3000 1000 0 50 100 150 260 250	5000 4000 2000 0 50 100 150 200 250	1437 1000 1000 0 1000 0 1000 1000 1000 100	0000 0000 1000 0 0 0 0 0 0 0 0 0 0 0 0	0000 4000 2000 1000 0 50 100 150 200 250	0000 0000 0000 0000 0000 0000 0000 0000 0000	5000 4000 500 500 1000 50 100 150 200 250	5000 4000 500 1000 500 10	5000 4000 2000 50 100 150 200 250
	Group6	9000 1 9000 - 49 9000 - 49	0000 5000 4000 3000 500 500 500 500	8000 1 5000 1 4000 1 5000 1 5000 1 5000 1 5000 1 5000 1 5000 1 69	5000 4000 3000 3000 3000 3000 3000 3000	5000 5000 4000 3000 3000 3000 3000 3000	80001 40001 40001 20001 20001	135	80001 4000- 1000- 1000- 1000- 1000-	9000 3000 3000 3000 3000 178
	0000 0000 0000 0000 0000 195	0000 0000 0000 0000 0000 0000 0000 0000 0000 00	00001 50001 50001 3000 3000 240	50 150 250 250 5001 5001 5001 5001 247	50 100 150 200 250 50001 50001 50001 2000 2000 2000	500 100 150 200 250 5000 5000 4000 267	50 100 150 250 250 5000 5000 5000 5000 5000 5000 50 5	500 100 150 200 200 5000 5000 5000 5000 5000 276	0000 0000 0000 0000 0000 0000 0000 0000 0000 299	0000-1 0000-1 0000-1 0000-1 0000-1 0000-1 0000-1 0000-1 0000-1 0000-1 000-1 000-1 000-1 000-1 000-1 00-1 00-1 0000-1 000-1 000-1 000-1 000-1 000-1 000-1 000-1 000-1 000-1 000-1 000-1 00000000
	00001 00001 00001 00001 00001 00001 00001 00001 00001	9000 9000 9000 9000 9000 9000 9000 9000 9000 9000 9	50001 50001 3000 3000 3000 3000 3000 300	500 100 150 200 250 500 100 150 200 250 500 100 150 200 250	50001 50001 50001 50001 30001 30001 30001 353	5000 5000 5000 3000 3000 3000 3000 3000 3000 3000 3001 371	500 100 150 200 250 5000 1 5000 1 5000 1 5000 1 5000 1 373	00001 00001 00001 00001 00001 00001 00001 00001 3800	5000 5000 5000 5000 5000 5000 423	9000-1 9000-1 9000-1 9000-1 9000-1 9000-1 9000-1 9000-1 9000-1 9000-1 9000-1 9000-1 900-10
	3000 3000 3000 3000 3000 452	⁵⁰⁰ <u>so</u> to to zo zo ⁵⁰⁰ 3000 3000 3000 455	1000 100 100 100 200 200 1000 1000 1000 1000 100 100 200 200 100 200 100 100 200 200 100 200 200 100 100 200 200 100 200 200 100 200 200 100 200 200 100 200 200 100 200 200 100 200 100 100 200 100 200 100 100 200 100 200 100 200 10	5000 50 100 150 200 250	5000 5000 5000 5000 5000 541	50001 50001 50001 50001 50001 50001 50001 50001 5557	598	0001 50001 50001 50001 50001 50001 618	0001 90 100 160 200 280 90001 90001 90001 8000 8000 8000 80001 80000 800 80000 80000 80000 80000 80000	0001 90001 90001 90001 90001 90001 90001 90001 90001 660
	1000 50 100 150 200 250 5000 5000 5000 5000 5000 673	0001 90 100 150 200 250 00001 00001 00001 00001 660	0000 50 100 150 200 250	5000 50 100 150 200 250 5000 3000 3000 5000 690	¹⁰⁰⁰ <u>50</u> 100 150 200 250 ⁵⁰⁰⁰ <u>4000</u> <u>4000</u> <u>692</u>	1000 50 100 150 200 250 5000 4000 3000 4000 4000 4000 4000 40	5000 50 100 150 200 250	1000 50 100 150 200 250 5000 3000 3000 3000 714	0001 50 100 150 200 250 50001 50001 50001 50001 50001 716	00001 50001 50001 50001 50001 50001 50001 721
	0000 50 100 150 200 250 0000 50000 728	00001 50 100 150 200 250 00001 00001 00001 730	2000 1000 50 100 150 200 250 00001 50001 50001 732	50001 50 100 150 200 250	50001 50 100 150 200 250	50001 50 100 150 200 250 50001 50001 50001 50001 50001 741	2000 50 100 100 200 200 2000 2000 2000 2000 20	00001 50 100 150 200 250	0000 <u>60 100 160 200 200</u> 00001 00001 00001 766	2000 50 100 150 200 250 2000 2000 2000 2000 2000 2000 2000 2000 20
	5000 50 100 150 200 250	2000 <u>60 100 150 200 250</u>	2000 500 500 500 500 500 500 789	5000 50 150 250 250	5000 50 160 150 260 250	2000 50 100 150 200 250	2000 <u>só rio rio zio zio</u> 5000 <u>5000</u> 8002 8002	2000 <u>só</u> rós rós zós zás 0000 0000 0000 1000 100 100 100	2000 60 100 150 200 250	2000 <u>60 100 150 200 250</u>
	30000 1000 50 100 150 200 250	3000 1000 50 100 150 200 250	2000 2000 50 100 150 200 250	2000 1000 50 100 150 200 250	1000 1000 50 100 150 200 250	2000- 2000- 50 100 150 200 250 5000-	2000 1000 50 100 150 200 250	2000 1000 50 100 150 200 250 500	5000- 1000- 50 100 150 200 250 5000- 5000-	0000 0000 50 100 150 200 250
	822 3000 50 100 150 200 250	823 1000 50 100 150 200 250	824 8000 50 100 150 200 250	50001 50001 50001 50001 50001 50001	827 1000 50 100 150 200 250 50001	838 2000 1000 50 100 150 200 250 5000	50001 50 100 150 200 250	855 2000 50 100 150 200 250 50 100 150 200 250	863 1000 50 100 150 200 250 50000	864 2000 1000 50 100 150 200 250
	866 30000 10000 00001	879 1000 1000 1000 1000 100 150 200 250 1000 1	885 3000 3000 3000 3000 300 300 300	900 1000 1000 50 100 150 200 250	902 902 500 500 500 500 500 500 500 5	913 913 500 500 500 500 500 500 500 50	921 50 100 150 200 200	939 939 1000 1000 1000 1000 1000 1000 10	948 948 0000 0000 0000 0000 0000 0000 00	949 949 00000 0000 0000 0000 0000 0000 0000 0000 0000 0000 0
	951	966 3000 3000 3000 50 100 150 200 250	970 970 970 970 970	974	993	996	1015 2000 2000 50 100 150 200 200	1026	1050 1000 1000 1000 1000 1000 100 100 200 200	5000 1107 1000 50 100 150 200 250

Days after 1st vaccination

Supplementary Figure 2. Antibody titer trajectory for individual participants stratified into different groups: The estimated antibody titer for each individual participant (solid lines) along with the observed data (closed dots) are depicted using the best-fit parameter estimates. G1, G2, G3, G4, G5, and G6 are shown in yellow, gray, green, light blue, blue, and pink, respectively. In each group, the curve of 100 was randomly selected for visualization because of the large number.

Supplementary Table 1. Details of query words and results of the literature review

#	Query Word	Results
1	"SARS-CoV-2" [tiab] OR "severe coronavirus disease 2019" [tiab] OR "COVID-19" [tiab] OR "severe acute respiratory syndrome coronavirus 2" [tiab] OR "coronavirus disease 2019" [tiab] OR "COVID-19*" [Mesh] OR "SARS-CoV-2*"	235,156
2	"vaccination*" [tiab] OR "vaccine*" [tiab] OR "NVX-CoV2373" [tiab] OR "CVnCoV" [tiab] OR "Ad26COV2S" [tiab] OR "BNT162 Vaccine*" [Mesh] OR "ChAdOx1 nCoV-19" [Mesh] OR "COVID-19 Vaccines*" [Mesh] OR "mRNA Vaccines" [Mesh] OR "RNA, Viral" [Mesh] OR "Vaccination*" [Mesh] OR "Vaccine Efficacy*" [Mesh] OR "Vaccines*" [Mesh] OR "2019-nCoV Vaccine mRNA- 1273*" [Mesh] OR "Ad26COVS1" [Mesh]	500,257
3	"Antibody level*" [tiab] OR "antibody response*" [tiab] OR "Antibody titer*" [tiab] OR "Humoral and Cellular Response*" [tiab] OR "humoral immune response*" [tiab] OR "humoral response*" [tiab] OR "immune response*" [tiab] OR "immunization" [tiab] OR "immunogenicity" [tiab] OR "Antibodies, Viral" [Mesh] OR "Antibody Formation" [Mesh] OR "Immunity, Humoral*" [Mesh] OR "Immunogenicity, Vaccine*" [Mesh]	557,862
4	"Second dose" [tiab] OR "second SARS-CoV-2 vaccine" [tiab] OR "2nd dose" [tiab] OR "second vaccination" [tiab] OR "two doses" [tiab] OR "two sequential doses" [tiab] OR "Two Vaccine Doses" [tiab] OR "two-dose" [tiab] OR "booster doses" [tiab] OR "second vaccine" [tiab] OR "Immunization, Secondary*" [Mesh]	30,432
5	"Cohort" [tiab] OR "Cross-Sectional" [tiab] OR "Follow-Up Studies" [tiab] OR "Prospective Studies" [tiab] OR "Cohort Studies" [Mesh] OR "Cross-Sectional Studies" [Mesh] OR "Follow-Up Studies" [Mesh] OR "Prospective Studies" [Mesh] OR "Observational Study*" [tiab]	3,119,085
6	1 AND 2	32,087
7	1 AND 2 AND 3	7,561
8	1 AND 2 AND 3 AND 4	1,311
9	1 AND 2 AND 3 AND 4 AND 5	440

#	Cohort Size	Study Period	Country	Vaccine Type	Population Characteristics	Interview Sheet	Times of Sampling	Sample 1	Sample 2	Sample final	Number of Participants Included in All Sampling	Samples of Neutralizing Antibody	Sample1 of Neutralizing Antibody	Reference
0	2526	270	Japan	BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna)	Community	Including	2	2526	2443	2443	2443	Including	2526	This study
1	3,991	200	Israel	BNT162b2 (Pfizer-BioNTech)	HCWs	Including	7	3991	2690	1370	693	Including	681	1
2	2,591	180	Italy	BNT162b2 (Pfizer-BioNTech)	Community	Not Including	4	1725	1641	2591	1215	Not Including	NA	2
3	1,935	90	Italy	BNT162b2 (Pfizer-BioNTech)	HCWs	Not Including	3	1935	NA	NA	NA	Including	1935	3
4	1,506	90	Israel	BNT162b2 (Pfizer-BioNTech)	HCWs	Including	2	1506	1209	1209	1194	Not Including	NA	4
5	1,487	41	Israel	BNT162b2 (Pfizer-BioNTech)	HCWs	Including	5	334	375	1487	22	Including	46	5
6	1,012	102	Turkey	CoronaVac (Sinovac)	HCWs	Including	2	1012	836	836	836	Not Includina	NA	6

Supplementary Table 2. Characteristics of the previously reported cohorts

#	Cohort Size	Vaccine Type	Country	Population Characteristics	Age	Sex	Obesity BMI>30	lmmun osuppr ession	Steroid	Hyperte nsion	Autoim mune disease	Heart disease	Lung disease	Kidney disease	Interval / Joint pain	Fever over 37.5	Other factors (P<0.05)	others factors (P>0.05)	Reference
1	3991	BNT162b2(Pfizer- BioNTech)	Israel	HCWs	+	+	+	+	NA	NA	+	NA	NA	NA	NA	NA	• the presence of two or more coexisting conditions (i.e., hypertension, diabetes, dyslipidemia, or heart, lung, kidney, or liver disease) • age- sex interaction	NA	1
2	1506	BNT162b2(Pfizer- BioNTech)	Israel	HCWs	+	+	NA	+	-	NA	NA	NA	NA	NA	NA	NA	Underlying conditions (i.e., hypothyroidism, autoimmune disease, cardiac disease, lung disease, immunodeficiency, chronic renal disease, and active oncological disease)	age-sex interaction Allergic reactions	4
3	1487	BNT162b2(Pfizer– BioNTech)	Israel	HCWs	+	-	-	+	NA	-	-	-	±	NA	NA	NA	NA	• Diabetes	5
4	1012	CoronaVac(Sinova c)	Turkey	HCWs	+	+	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	6
5	632	BNT162b2(Pfizer– BioNTech)	Italy	Patients: cancer	-	+	+	+	+	NA	NA	NA	NA	NA	NA	NA	Concomitant disease Therapeutic setting Active anticancer treatment	• ECOG PS • Number of metastatic sites • Type of Metastases	7
6	552	CoronaVac(Sinova c)	UK	Community	+	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	8
7	548	BNT162b2(Pfizer– BioNTech) or CoronaVac(Sinova c)	Turkey	HCWs	+	-	+	+	NA	NA	NA	NA	NA	NA	NA	NA	occupation (Medical doctor, Nurse, other healthcare workers) Presence of chronic disease (yes or no) • Pneumococcal vaccine (yes or no)	• smoking (Never,Current,Ever) • Vaccination status (influenza vaccine)	9
8	539	BNT162b2(Pfizer-BioNTech)	Sweden	Patients: primary immunodeficien cy disorders (PID) or human immunodeficien cy virus (HIV), HSCT/chimeric antigen receptor T (CAR T) cell therapy, solid organ transplantation (SOT), or chronic lymphocytic leukemia (CLL)	-	-	NA	-	NA	NA	NA	NA	NA	NA	NA	NA	All immunocompromised patients•primary immunodeficiency • hematopoietic stem cell transplantation • solid organ transplantation • chronic lymphocytic leukemia • Patients goups (HIV vs PID, HSCT, SOT, CLL) • HSCT- (GvHD absent vs severe) • SOT(Time to tranplantation, Creatinine baseline, MMF) • SOT-type of organ(Liver vs Kidney) • CLL(IgG baseline)• CLL-subgroups(Indolent vs Ibrutinib)	human immunodeficiency virus Lymphocyte count at baseline • PID(Age,Sex,Co-morbidity, IgG at baseline, Autoimmunity, Malignancy) • PID-sub group(CVID vs CD4 cytop., Monogenic disease, Other, XLA) • HSCT-subgroups(Late vs Intermediate) • HSCT(GVHD absent vs miled,moderate) • HSCT(Age,Sex,GVHD) • SOT- type of organ(Liver vs Kidney/pancreas) • SOT(Age,Sex,Tacrolimus) • CLL(Age,Sex) • CLL- subgroups(Indolent vs Off ibrutinib, Previous CD20-mAb)	10
9	481	ChAdOx1 nCoV- 19(Astra Zeneca) or BBV-152(Bharat Biotech)	India	HCWs	+	-	-	NA	NA	+	NA	-	NA	NA	NA	NA	Co-morbidities (No co- morbidities vs Any co-morbidities) Vaccine type (Vocaxin vs Covaxin) • Previous infection	• Blood Group • Type2 Diabetes Mellitus (No vs Yes) • Duration of T2DM (<5years vs 5-10 years, >10years) • Dyslipidaemia • Ischemic Heart Disease	11
10	289	BNT162b2(Pfizer– BioNTech)	Israel	Patients:Dialysis	-	-	NA	NA	NA	NA	NA	NA	NA	+	NA	NA	● dialysis + Post COVID-19 Infection ● Albumin	 hemodialysis peritoneal dialysis Diabetes Dialysis vintage (dialysis adequacy HD,dialysis adequacy PD) 	12
11	276	BNT162b2(Pfizer– BioNTech) or ChAdOx1 nCoV- 19(Astra Zeneca)	Greece	Patients: monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM)	-	+	-	+	NA	NA	NA	NA	NA	NA	NA	NA	● Multiple myeloma ● treatment type:anti-BCMA-based regimens(belantamab mafodotin and anti-CD38 monocolonal antibodies),anti-CD38-based regimens ● lymphopenia ● low levels of IgA	MGUS, Smoldering multiple myloma International Staging System:ISS(Stage1 vs 2,3) • Revised International Staging System:RISS(Stage1 vs 2,3) • Myeloma type(IgG vs IgA,IgM,KLC,LLC) • low levels of IgM,IgG • treatment type: PI/IMID-based combinations, I enalidomide maintenance	13

Supplementary Table 3. Characteristics of the vulnerable population

12	248	BNT162b2(Pfizer- BioNTech)	France	Patients: receiving ICI, patients with pneumonectomy or chronic radiation pneumonitis, pati ents on oral tyrosine kinase targeted therapy (tyrosine kinase inhibitors [TKIs]); and patients without systemic therapy	+	+	NA	÷	÷	NA	 chemotherapy,targeted therapy,bevacizumab • without systemic therapy within 3 months single-agent ICI treatment within last 3 months 	chemotherapy vs immunotherapy	14						
13	200	BNT162b2(Pfizer– BioNTech)	Japan	Patients: hemodialysis (HD)	+	-	-	NA	NA	+	NA	+	NA	NA	NA	NA	History of stroke, Dementia White blood cell count	• Creatinine • Blood urea nitrogen • Hemoglobin • White blood cell count • Mean KT/V • Dialysis mellitus	15
14	200	BNT162b2(Pfizer- BioNTech)	Denmark	Patients: solid organ transplant (SOT) recipients	+	-	-	±	NA	NA	NA	+	NA	NA	NA	NA	Transplanted <1 year before vaccination • Immunosuppressive treatment (Corticosteroids) • Type of organ transplanted (Liver vs Kidney, Lung) • Comorbidities (Diabetes mellitus, De novo non- skin cancer)	Immunosuppressive (No antimetabolite vs Azathioprine,Mycophenolate)• Immunosuppressive(Calcineurin inhibitor vs mTOR inhibitor) • Comorbidities(Chronic pulmonary disease)	16
15	194	BNT162b2(Pfizer– BioNTech) or mRNA- 1273(Moderna)	Switzerlan d	Patients: allogeneic hematopoietic cell transplantation (allo-HCT) graft- versus-host disease (GVHD)	+	-	NA	IST • underlying disease • allo- HCT resipients • preinfection	chronic GVHD	17									
16	185	CoronaVac(Sinova c)	Thailand	HCWs	+	-	NA	 occupation 	18										
17	156	BNT162b2(Pfizer-BioNTech)	Portugal	Patients: hemodialysis (HD)	+	-	-	-	-	-	NA	-	NA	+	NA	NA	• Leukemia	Laboratory parameters (Hemoglobin, Serum slbumin, Ferritin, nPCR, CRP,25(OH) D3) Comorbidities (Diabetes mellitus, Chronic liver disease, Rheumatic disease, Past Kidney transplant) • Medication (Erythropoiesis-stimulating agent,Angiotensin-converting- enzyme inhibitor,Statins,Corticosteroid,Oth er immunossupressor/immunomodul ator,Tacrolimus,Non-steroidal anti-inflammatory drug,Antlithrombotic,Anti-HBc positivity)	19
18	155	CoronaVac(Sinova c)	Turkey	Patients: kidney transplant recipients (KTRs) and hemodialysis (HD)	+	NA	-	NA	Absolute lymphocyte count Neutrophil lymphocyte ratio 25- OH-vitamin D3	20									
19	150	BNT162b2(Pfizer– BioNTech)	Netherland s	Patients: previously SARS-CoV-2- infected	-	±	NA	 illness on set dating >1 year before vaccination severe disease outcomes 	NA	21									
20	142	BNT162b2(Pfizer– BioNTech)	Canada	Patients: receiving in- center hemodialysis	-	_	NA	+	NA	NA	NA	NA	22						
21	136	BNT162b2(Pfizer– BioNTech)	France	Patients: rheumatic and musculoskeletal	-	-	NA	NA	-	NA	Mycophenolate Methotrexate	• At least one BILAG score ≥B • C3, g/L • dsDNA antibodies, IU/mL • Detectable IFN-α ● Total	23						

				diseases (RMDs) and associated immune- modulatory treatments														serum IgA, g/L • Total serum IgM, g/L • Lymphocytes count, G/L • Hydroxychloroquine • Azathioprine • Belimumab • Other immunosuppressor	
22	136	BNT162b2(Pfizer- BioNTech) or CoronaVac(Sinova c) or ChAdOx1 nCoV-19(Astra Zeneca) or Ad26.COV2.S(Jan ssen)	Portugal	HCWs	-	-	NA	Vaccine reactogenicity	24										
23	126	BNT162b2(Pfizer– BioNTech)	Germany	HCWs	NA	Selenium (Se) supplementation	25												
24	110	BNT162b2(Pfizer– BioNTech) or ChAdOx1 nCoV- 19(Astra Zeneca) or mRNA- 1273(Moderna)	France	HCWs	+	-	-	NA	Comorbidity	26									
25	109	BNT162b2(Pfizer- BioNTech)	Finland	Patients: multiple myeloma (MM) and myeloproliferativ e malignancies (MPM)	-	-	-	+	NA	• multiple myeloma (MM) • myeloproliferative malignancies (MPM) •Treatment (Daratumumab-based vs PI- based/Imids-based alone or in combo without daratumumab)	Lines of therapy Lymphocyte count Time from diagnosis to vaccination	27							
26	103	BNT162b2(Pfizer– BioNTech)	U.S.	Patients: solid tumors	NA	NA	NA	-	NA	• cancer	NA	28							
27	100	CoronaVac(Sinova c)	China	HCWs	+	-	NA	 interval between two doses 	NA	29									
28	75	BBIBP- CorV(Sinopharm)	China	community	+	NA	+	NA	absolute lymphocyte count high levels of serum SAA (serum amyloid A) elow T3 before vaccination Higher levels of absolute lymphocyte count accompanied by lower serum SAA	biochemical routine indexes (blood cell counts and differentials,ALT,AST,GGT,CHE, ALP,TBA,LDH,CRP) ethyroid function markers except T3 • comorbidities	30								
29	49	BNT162b2(Pfizer– BioNTech)	Japan	HCWs	+	-	NA	+	alchol drinking habits	 Smoking habits Allergies Other side effects after vaccination 	31								
30	44	BNT162b2(Pfizer– BioNTech)	Italy	Patients: chemotherapy	+	NA	±	NA	oncolocy(After 1 months) Comorbidity Progressive disease Chemotherapy in progress FIGO stage	32									
31	43	BNT162b2(Pfizer– BioNTech)	Germany	Patients: dialysis	NA	+	NA	NA	 oncolocy(After 3 months) 	NA	33								
32	41	BNT162b2(Pfizer– BioNTech)	Japan	Patients: solid tumors	NA	NA	NA	+	NA	 cytotoxic chemotherapy immune checkpoint inhibitors 	 cytotoxic chemotherapy vs immune checkpoint inhibitors 	34							
33	40	BNT162b2(Pfizer– BioNTech) or mRNA- 1273(Moderna)	U.S.	HCWs	NA	-	NA	 Previous infection 	NA	35									
34	29	BNT162b2(Pfizer– BioNTech)	Israel	Patients: primary brain tumors	_	+	NA	NA	+	NA	primary brain tumors (PBTs)	Treatments (Surgery,Temozolomide,Elapsed time from vaccination) ● Diagnosis(Artypical meningioma, Glioblastoma multiforme, Oligodendroglioma)	37						

Parameter or variable	Decay rate of antibody- secreting cells	Maximum <i>de</i> <i>novo</i> production of antibody by 1 st vaccination	Delay of antibody- secreting cells induction after 1 st vaccination.	Steepness at which induction increases with increasing the amount of mRNA	Amount of mRNA satisfying $P_i/2$	Maximum <i>de</i> <i>novo</i> production of antibody by 2 nd vaccination	Delay of antibody- secreting cells induction after 2 nd vaccination.
Symbol	μ	H_1	η_1	т	K	H_2	η_2
Unit	day⁻¹	AU/mL	day		μg/0.5mL	AU/mL	day
Individual e	stimated param	neters for S1 to S	12				
<i>S</i> 1	0.885346	650.518	12.5269	0.0373144	33900	5227.34	4.21433
<i>S</i> 2	0.885346	760.114	12.5109	0.028673	33900	5035.79	4.23423
<i>S</i> 3	0.885346	2375.11	12.5096	0.0223842	33900	7562.82	3.85759
<i>S</i> 4	0.885346	790.745	12.4927	0.0611514	33900	7304.66	3.95306
<i>S</i> 5	0.885346	942.686	12.5169	0.0250174	33900	5638.12	3.91276
<i>S</i> 6	0.885346	448.87	12.5243	0.0851651	33900	3828.1	4.24752
<i>S</i> 7	0.885346	1848.01	12.5471	0.0272096	33900	9073.94	4.2513
<i>S</i> 8	0.885346	567.839	12.5409	0.0523284	33900	4673.2	4.71178
<i>S</i> 9	0.885346	1835.9	12.5428	0.0365247	33900	7517.48	4.59114
<i>S</i> 10	0.885346	1201.77	12.5109	0.0625655	33900	5916.28	4.17894
<i>S</i> 11	0.885346	736.229	12.5086	0.0700219	33900	4118.67	4.54006
<i>S</i> 12	0.885346	1369.65	12.5409	0.0488345	33900	8226.08	4.23969
Population	estimated para	meters					
	0.885346	975.297	12.52	0.0437653	33900	6035.142	4.25

Supplementary Note 1: Literature review

This comprehensive literature review aimed to characterize the Fukushima vaccination cohort from previous cohort studies and to identify the factors contributing to the vulnerability of certain populations. A total of 440 articles published up to March 23, 2022, were collected using PubMed. Details of the search terms used in this analysis are provided in **Supplementary Table 1**. In the first step, a group of two or three authors (YT, MK, MY, TA, YS) screened and retrieved articles according to the following two criteria: (i) report evaluating antibody titer testing of human blood samples after two doses of SARS-CoV-2 vaccine; (ii) report collecting at least two blood samples after two doses of SARS-CoV-2 vaccine, and 92 articles met the criteria. Fig 1F shows the overall distribution of the cohort size and study period of the included papers. Study period was defined as the maximum period between the first vaccination and the completion of the last sampling, and *cohort size* was defined as the maximum number of participants who had at least one sample collected at certain sampling times during the period. The median cohort size was 103 and the median study period was 150 days, and six articles were found to have a cohort size of 1,000 or more (Supplementary Table 2). Next, we extracted and analyzed the factors contributing to vulnerable population status from 40 of 92 papers, including interview sheets. 6 of which were excluded because they did not analyze factors of vulnerability (Supplementary Table 3). From this literature review, we found that only the Fukushima cohort (1) consecutively sampled more than 2,000 of the same individuals with less dropout (only 3.3%): (2) included an interview sheet for all participants; (3) targeted "communities" (including non-HCWs); and (4) measured several modalities of antibody titers including neutralizing activity (Supplementary Table 2).

Supplementary Note 2: Stratifying time-course pattern of antibody dynamics

For the purpose of stratification of the individual vaccine-elicited antibody response, we first applied unsupervised random forest clustering to the individual "reconstructed" antibody dynamics of 2,407 participants (e.g., **Supplementary Fig 2**) but failed to divide the time-course pattern of antibody dynamics into different clusters (data not shown). To overcome this problem, we employed an idea of "feature engineering": extracting features to improve the quality of results from a machine-learning process, compared with supplying only the raw data to it. We quantified the peak, duration, and area under the curve of the reconstructed antibody dynamics as their features (Extended Data Fig 5D). Interestingly, the unsupervised random forest clustering based on these features in addition to our estimated individual parameters (i.e., m and H_2) identified 10 clusters that clearly discriminated the time-course patterns (Extended Data Fig 2AB). Since the time-course patterns of clusters 2, 3, 6, and 7 were similar and they were close together in two-dimensional Uniform Manifold Approximation and Projection (UMAP) embeddings (Extended Data Fig 2A), we merged these clusters into one group. In addition, we removed cluster 8 from further evaluation (i.e., we removed 245 individuals, around 10%, of the 2.407 participants in the Fukushima cohort) on the grounds that their reconstructed antibody dynamics with estimated parameters may not be reasonable. This is because their antibody titers measured from two blood samples showed statistically significantly small differences ($p < 1.0 \times 10^{-16}$ by Welch two sample t-test) and their sampling intervals were significantly shorter than the others (p =0.01 by Welch two sample t-test) (Extended Data Fig 2C). This problem will be solved by adjusting for the timing of their blood sampling in our future study of booster vaccinations. Finally, we obtained 6 groups to evaluate the stratification in further detail (Fig 2A).

Supplementary Note 3: Inter-relationship of various features

We visualized the inter-relationship of various features using principal component analysis (PCA) based on their correlation matrix (**Fig 3F** and **Extended Data Fig 3C**). We found that the first principal axis, explaining 25.9% of the variance, represents titers: the antibody titers and the dynamic parameters of each individual (i.e., their peak, duration, and area under the curve, m and H_2) were located in the third quadrant of this PCA plane. The adverse events were in the second quadrant, suggesting their closeness to high antibody titers. However, most questionnaire items about basic demographic information and lifestyle habits remained in the middle, indicating their relatively minor role. A notable exception was age, which was inversely correlated with titers and was indeed situated in the fourth quadrant. By contrast, the second principal axis, explaining 9.8% of the variance, represents comorbidities and medication. Our stratification combines these information and places G1, G2, and G4 in the third quadrant; G3 in the middle; and G5 and G6 in the fourth quadrant near the comorbidities cluster and age.

References

- 1. Levin, E.G., *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. *N Engl J Med* **385**, e84 (2021).
- 2. Papadopoli, R., *et al.* Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population. *Vaccines (Basel)* **9**(2021).
- 3. Buonfrate, D., *et al.* Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study. *Clin Microbiol Infect* **27**, 1845-1850 (2021).
- 4. Shachor-Meyouhas, Y., *et al.* Immunogenicity trends 1 and 3 months after second BNT162B2 vaccination among healthcare workers in Israel. *Clin Microbiol Infect* **28**, 450 e451-450 e454 (2022).
- 5. Lustig, Y., *et al.* BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. *Lancet Respir Med* **9**, 999-1009 (2021).
- 6. Demirbakan, H., Kocer, I., Erdogan, M. & Bayram, A. Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers. *Public Health* **205**, 1-5 (2022).
- 7. Di Noia, V., *et al.* Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: The urgent need of the additional dose! *Eur J Cancer* **165**, 169-173 (2022).
- 8. Ramasamy, M.N., *et al.* Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet* **396**, 1979-1993 (2021).
- 9. Caglayan, D., *et al.* An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey. *J Med Virol* **94**, 2212-2221 (2022).
- 10. Bergman, P., *et al.* Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. *EBioMedicine* **74**, 103705 (2021).
- 11. Singh, A.K., *et al.* Humoral antibody kinetics with ChAdOx1-nCOV (Covishield) and BBV-152 (Covaxin) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study. *Diabetes Metab Syndr* **16**, 102424 (2022).
- 12. Berar-Yanay, N., *et al.* Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients. *J Clin Med* **11**(2021).
- 13. Terpos, E., *et al.* The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. *Blood Cancer J* **11**, 138 (2021).
- 14. Gounant, V., *et al.* Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. *J Thorac Oncol* **17**, 239-251 (2022).
- Kitamura, M., *et al.* Low humoral immune response to the BNT162b2 vaccine against COVID-19 in nursing home residents undergoing hemodialysis: a case-control observational study. *Ren Replace Ther* 8, 8 (2022).
- 16. Hamm, S.R., *et al.* Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls. *Front Immunol* **13**, 832501 (2022).

- 17. Huang, A., *et al.* Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation. *Transplant Cell Ther* **28**, 214 e211-214 e211 (2022).
- 18. Benjamanukul, S., *et al.* Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers. *J Med Virol* **94**, 1442-1449 (2022).
- 19. Weigert, A., *et al.* Longitudinal Analysis of Antibody Responses to the mRNA BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis: A 6-Month Follow-Up. *Front Med* (*Lausanne*) **8**, 796676 (2021).
- 20. Dheir, H., *et al.* Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients. *J Med Virol* (2022).
- 21. van Gils, M.J., *et al.* A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. *Cell Rep Med* **3**, 100486 (2022).
- 22. Yau, K., *et al.* Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis. *JAMA Netw Open* **4**, e2123622 (2021).
- 23. Moyon, Q., *et al.* BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. *Ann Rheum Dis* **81**, 575-583 (2022).
- 24. Guiomar, R., *et al.* Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination. *Vaccines* (*Basel*) **10**(2022).
- 25. Demircan, K., *et al.* Humoral immune response to COVID-19 mRNA vaccination in relation to selenium status. *Redox Biol* **50**, 102242 (2022).
- 26. Bonnet, B., *et al.* Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers. *Front Immunol* **13**, 842912 (2022).
- 27. Pimpinelli, F., *et al.* Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. *J Hematol Oncol* **14**, 81 (2021).
- 28. Shroff, R.T., *et al.* Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. *Nat Med* **27**, 2002-2011 (2021).
- 29. Chen, Y., *et al.* Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. *Clin Microbiol Infect* **28**, 410-418 (2022).
- 30. Zhang, J., *et al.* Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects. *Front Cell Infect Microbiol* **11**, 791660 (2021).
- 31. Ikezaki, H., Nomura, H. & Shimono, N. Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers. *J Infect Chemother* (2022).
- 32. Palaia, I., *et al.* Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study. *Vaccines (Basel)* **10**(2021).
- 33. Schrezenmeier, E., *et al.* Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. *Front Immunol* **12**, 690698 (2021).
- 34. Funakoshi, Y., *et al.* Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer. *J Infect Chemother* **28**, 516-520 (2022).
- 35. Lucas, C., *et al.* Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. *Nature* **600**, 523-529 (2021).
- 36. Beilhack, G., *et al.* Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients the Vienna Cohort. *Front Immunol* **12**, 780594 (2021).
- 37. Massarweh, A., *et al.* Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study. *J Neurooncol* **156**, 483-489 (2022).



















